Construction of Random Epitope Insertion cDNA libraries and Consecutive Selection for Folding Competent Proteins in Sz. pombe: a novel approach by Lyngsø, Christina & Mortensen, Uffe Hasbro
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 17, 2017
Construction of Random Epitope Insertion cDNA libraries and Consecutive Selection
for Folding Competent Proteins in Sz. pombe: a novel approach
Lyngsø, Christina; Mortensen, Uffe Hasbro
Publication date:
2006
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Lyngsø, C., & Mortensen, U. H. (2006). Construction of Random Epitope Insertion cDNA libraries and
Consecutive Selection for Folding Competent Proteins in Sz. pombe: a novel approach.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Construction of Random Epitope Insertion cDNA libraries and  
Consecutive Selection for Folding Competent Proteins 
 in Sz. pombe: a novel approach 
 
 
 
 
 
 
Danmarks Tekniske Universitet  
 
PhD Thesis 
Christina Lyngsø 
  - 2 - 
  - 3 - 
 
 
ABSTRACT 
Pharmexa's main research area focuses on therapeutic vaccines against diseases where a 
harmful self-protein is involved. In order to make a vaccine against a self-protein, the inherent 
tolerance of the immune system to self-antigens must be by-passed or broken. This is achieved 
by immunization with a modified form of the harmful protein. 
The modification consists of an insertion of a highly immunogenic foreign Th-cell epitope in 
the target protein sequence. However, the Th-cell epitope is a 15-20 amino acid long peptide, 
which can destabilise the protein. Therefore, the modified protein may not be viable or its 
three-dimensional structure may be altered considerably. The aim of the present project has 
been to develop a systematic approach to find permissive insertion sites in protein vaccine 
candidates.  
This strategy comprises: construction of a random insertional library of the protein target, 
representing insertions at all amino acid positions of the target using a transposon, and 
screening and selection for folded proteins from the insertion library in Sz. pombe. For 
screening, the cDNA library is fused upstream to the invertase cDNA and expressed in Sz. 
pombe as secreted fusion proteins with the invertase moiety. The chimeric proteins capable of 
folding and hence expression, are then selected based ability to genetically complement 
invertase activity in a host cell lacking an endogen invertase gene. In this study TNF-α was 
chosen as model protein. 
The presented insertion library, which represents 17,500 distinct epitope insertions was 
transformed in Sz. pombe and screened for invertase activity. Out of 36,000 transformed 
colonies, 22 were found positive. In these permissive sites for insertion of the epitope were 
found mostly within the N-terminal region of the protein, as well as C-terminal and the in 
loops between beta-strands and at the ends of beta-strands. Thus, most insertion sites 
coincided with sites predictable by rational design and importantly, insertion sites, not 
predictable as permissive sites by rational design were also identified. Finally, 5 of the 22 
TNF-α insertion variants, in which the invertase moiety had been removed by sub-cloning, 
were chosen for testing for expression in E. coli, Sz. pombe, and Drosophila cells. All tested 
proteins were expressed, whereas 2 negative controls (bearing insertions, but not displaying 
invertase activity) were not expressed, validation the approach. 
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RESUMÉ 
Konstruktion af et bibliotek af tilfældigt indsatte Th-celle epitoper og efterfølgende screening 
og selektion af foldningskompetente proteiner I Sz. pombe: en ny tilgang. 
Pharmexa A/S er en bioteknologisk virksomhed inden for aktiv immunterapi og vacciner til 
behandling af alvorlige kroniske sygdomme, hvor skadelige selv-proteiner er involveret. For at 
lave vacciner mod selv-proteiner må den naturlige tolerance mod disse omgås eller brydes. 
Dette opnås med immunisering med en ændret form af det skadelige protein. Ændringen 
består af indsættelsen af en immunogent fremmed T hjælper celle epitop i sekvensen af target 
proteinet, hvilket synligør proteinet for immunesystemet. Epitopet består af 15-20 
aminosyrer, og dette relativt lange peptid kan potentielt destabilisere proteinet, hvorved det 
mister foldningskompence eller dets tredimensionelle struktur er ændret betydeligt.  
Målet med dette projekt har været, at udvikle en metodisk tilgang til, at finde 
indsættelsessteder af et epitop tolereret af selv-proteiner. Til dette konstrueres, ved hjælp af 
et transposon, et bibliotek med tilfældigt indsatte epitoper i target-proteinet. I biblioteket 
findes derfor varianter repræsenterende epitoper indsat på alle positioner mellem 
aminosyrerne. Efterfølgende selekteres foldningskompetente proteiner fra biblioteket, ved at 
cDNAet fra biblioteket fusioners opstrøms til et cDNA, der koder for invertase. 
Fusionsproteinet er desuden koblet til et signal peptid og kan derfor sekreteres til 
cellevæggen. Invertase er et enzym, der er essentielt for gærcellers vækst på almindeligt 
sukker, og biblioteket af chimeriske proteiner udtrykkes i Sz. pombe stamme deleteret for 
invertase genet. Selektionen foregår ved, at kun foldede proteiner vil kunne nå cellevæggen, 
hvor invertase skal være for at være aktiv pga. en kvalitets kontol, der foregår i 
sekresionsapperatet. Dvs. at fusionsproteiner med foldningskompetence vil da kunne vælges 
baseret på deres evne til at komplementere invertase aktivitet, og dermed opretholde vækst.  
I dette studie er TNF-α valgt som modelprotein, hvorfra der er blevet lavet et 
insertionsbiblioteket, repræsenterende 17.500 distinkte epitop indsættelser. Ud af 36.000 
transformerede kolonier, screenet blev 22 fundet positive og indsættelsesstedet analyseret. 
Epitopet hovedsageligt fundet i det N- terminale område af proteinet, dog var der også nogle 
C-terminalt og i loops mellem sekundære strukturer. Følgelig faldt de fleste positioner for 
epitopeindsættelser sammen med steder, som er forudsigelige ved hjælp af rationel design. 
Interessant nok var der et epitopeindsættelsessted, som ikke ville kunne forudsiges. Dette 
giver en indikation af anvendeligheden af denne empiriske metode. Til slut, valideredes 
systemet ved at udtrykke 5 af de 22 TNF-α varianter i E. coli, Sz. pombe, og Drosophila celler. 
Alle de testede proteiner kunne udtrykkes. 
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PREFACE 
 
This PhD project has been part of the industrial PhD initiative, jointly founded by Pharmexa 
A/S and the Danish Ministry of Science. The project has been carried out mainly at the 
division of Molecular Biology and Expression at Pharmexa and in part at the laboratory DNA 
repair at BioCentrum, DTU headed by Uffe Mortensen. Florence Dal Degan, research scientist 
at Pharmexa, and Uffe Mortensen have been supervisors. 
 
Technician Helene Lykkegaard has carried out part of the practical work, Sven Muller has 
made the plasmid PADRE-pVax plasmid, and Søren Kjærulff the Sz. pombe screening host 
and the Sz. pombe vector. The Sz. pombe strain Eg660 ∆inv1::ura4+ has kindly been provided 
by O. Nielsen, The University of Copenhagen. 
 
The results presented here have formed the basis of patent applications 16535DK00 and 
16535US00; Random Insertion of Peptides. These were filled at the May 31th, 2006. 
Furthermore, the results will be published in a peer reviewed international journal. 
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LIST OF ABBREVIATION 
Adh Alcohol Dehydrogenase 
APC Antigen presenting cell 
ARS Autonomous replication sequence 
BiP Immunoglobulin heavy chain binding protein 
CAT Chloramphenicol acetyl-transferase  
CFA Complete Freund's adjuvant 
COPII Cytoplasmic coat protein II 
Cpy Carboxy-peptidase Y 
E. coli Escherichia coli 
E2 Ubiquitin conjugation enzymes  
E3 Ubiquitin ligases  
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ER Endoplasmic reticulum 
ERAD ER-associated degradation 
ERGIC-53 ER-Golgi intermediate compartment protein 53 
ERp57 Endoplasmic reticulum protein 57 
FACS Fluorescence-activated cell sorting  
GFP Green florescent protein 
GPR170 Glucose-regulated protein 170 
GT UDP-Glc:glycoprotein glucosyltranferase 
HAC1 Homologous to ATF/CREB 1 
HER-2 Human epidermal growth factor receptor-2 
hCMV Human cytomegalovirus 
HIV Human immunodeficiency virus 
HLA Human Leucocyte Antigen 
Hsp70 Heat chock factor 70 
HU Histone like protein 
IHF Integration Host Factor 
Inv1 Invertase gene in Sz. pombe 
Ire1 Inositol requiring protein  
ITR Terminal inverted repeat  
kDa Kilo Dalton 
LacZ-α Subunit of the enzyme β-galactosidase  
METI Ministry of Economy, Trade and Industry 
NMR Nuclear magnetic resonance 
nmt1 No message in thiamine promoter 
OD Optical density 
OST Oligosaccaryl-transferase complex 
PADRE Pan DR helper T cell epitopes  
PDI Protein disulfide isomerase 
RANKL Receptor activator of nuclear factor (NF)-κB ligand 
Rpm Rounds per minutes 
S. cerevisiae Saccharomyces cerevisiae 
Sec61 Secretion complementation protein 61 
SRP Signal recognition particle 
SV40 Simian virus 40 
Sz. pombe Schizosaccharomyces pombe 
TACE TNF-α converting enzyme 
TCR T-cell receptor 
Th-cells T-helper cells 
TNF-α Tumor necrosis factor alpha 
TNFR1 and TNFR2 Tumor necrosis factor alpha receptor 1 and 2 
TRAM Translocating chain-association membrane 
UPR Unfolded protein response 
YEA Yeast extract + adenine media 
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AIM 
A key feature of Pharmexa’s AutoVac technology depends on the insertion of a peptide epitope 
into a give protein, to generate protein vaccines. Insertion of peptides into proteins may 
interfere with protein folding and structure. Presently, permissive insertion sites are 
predicted based on rational design and tested individually experimentally. The success rate of 
this approach is low as permissive sites for insertion have proven difficult to predict, and the 
successful generation of AutoVac vaccine candidates is therefore cumbersome and time 
consuming. 
The aim of the presented project has been to develop a method that in principle allows to find 
all permissive insertion sites for foreign epitope into a given target protein. The method is 
based on the genetic screen in a eukaryotic host that selects for folding competent proteins 
from a library containing all possible AutoVac candidates. This method should not depend on 
any functional or structural features of the target molecule, and should therefore, be 
applicable to any protein of interest.” 
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INTRODUCTION 
Therapeutic vaccination by Autovac™ molecules 
Pharmexa’s main area of research is the development of therapeutic protein vaccines against 
diseases where harmful self-proteins are involved. The rationale behind this vaccine is to 
induce a strong, but controlled, antibody response against harmful self-proteins to reduce 
their levels, thereby creating a therapeutic effect  (Dalum et al., 1996). Similarly to 
prophylactic vaccines, preventing infectious disease, therapeutic vaccines against self-proteins 
are based on a similarity to the putative cause of the disease. However, since these proteins 
are self-antigens, the immune system does not identify them as pathogenic, so the inherent 
tolerance of the immune system to self-antigens must be by-passed or broken. 
To develop this vaccine, a genetic modification of the harmful protein is made by insertion of a 
foreign immuno-dominant T-helper cell epitope in its sequence, and the resulting modified 
antigen is expressed as a recombinant protein. The modified protein is able to evoke an 
immune response towards the wild-type protein. 
Such recombinant proteins represent the proprietary technology of Pharmexa named 
AutoVac The vaccination can be used as preventive therapy to acquire disease resistance (as 
Receptor activator of nuclear factor (NF)-κB ligand (RANKL) in bone destruction  (Juji et al., 
2002)), to stop a disease state from developing further (as Tumor necrosis factor alpha (TNF-
α)) in rheumatoid arthritis  (Dalum et al., 1999)), or it can be used as therapeutic intervention 
against an already established disease state (as Human epidermal growth factor receptor-2 
(HER-2 ) in breast cancer  (Renard et al., 2003)). 
Immunological background of the vaccine 
The humoral immune response is comprised of B-cells and T-helper (Th) cells collaborating in 
starting the production of antibodies, in that B cell clonal selection and differentiation into 
antibody producing plasma cells are controlled in an antigen specific manner by Th-cells  
(Rajewsky et al., 1969) (Figure 1A). Antigen presenting cells (APC) randomly and continuously 
endocytose proteins in the bloodstream - self as well as foreign - without any prior selection  
(Kourilsky et al., 1987). The engulfed proteins are processed into small 15 amino acid 
fragments by the cells, and displayed on Human Leucocyte Antigen (HLA) class II receptors 
on the cell surface. The peptide fragments presented are specific parts of the proteins termed 
epitopes. Here, Th-cells continuously test if the displayed fragment can bind their T-cell 
receptors (TCR). If there is a match, the fragment is considered foreign, as Th-cells 
recognising self-peptides have been eliminated by clonal selection in the spleen and lymph 
INTRODUCTION 
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nodes. The Th-cell, matching the fragment presented on APC, are activated and stimulated to 
proliferate by the APC. The activated Th-cells can now provide help (via cytokines and other 
signals) for activation and proliferation of B-cells presenting a fragment identical to the one 
originally recognised by the Th-cell  (Rock et al., 1984). Thus, in order to be activated, B-cells 
must be able to present the Th-epitope on their HLA II receptors. This is done by a small 
subset of the B-cells that, by using their cell surface bound antibody receptors, recognise, and 
bind three-dimensional structures on the foreign antigen. After engulfment by he B-cells, the 
protein is processed inside a proteolytic compartment of the cell  (Mouritsen et al., 1992), and 
will be presented as several small fragments on the cell surface HLA II receptors  
(Lanzavecchia and Bove, 1985). If the B-cell displays the same epitope recognised by the Th-
cells, it receives help and starts to secrete antibodies capable of cross-reacting with the 
antigen  (Liu et al., 1992). These antibodies have the same specificity as the B-cell antibody 
receptors originally recognising the foreign protein.  
Figure 1. Outline of the Immune response against AutoVac protein 
A Th-cell epitope is inserted into the primary sequence of the target. After immunisation the recombinant 
protein is endocytosed by APC and, after degradation, peptides are presented on the cell surface in complex 
with HLA class II. Th cells are not normally activated by the auto-peptides, as Th cells recognizing this 
complex have been down regulated, hence the tolerance against self proteins. Th cells recognizing the T cell 
epitope-HLA II are, on the contrary, activated and ready to activate B cells presenting the same peptide. 
Resting B cells recognize and endocytose antigens through membrane bound antibodies. B cell clones both 
recognizing the Th-cell epitope but also and more importantly, the target protein bind and endocytose vaccine 
molecule and will interact with epitope activated Th cells. The resting B cells will proliferate and differentiate 
into antibody producing plasma cells. 
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The vaccine strategy is based on the fact that the Th-cell epitope and the B-cell epitopes are 
not generally coinciding  (Lanzavecchia, 1985) (Figure 1B). Vaccine molecules are comprised of 
two entities: a strong foreign Th-cell epitope and a therapeutic relevant protein. A small 
proportion of B-cells is self-reacting and has antibody receptors specific for the self-antigen 
corresponding to the vaccine molecule  (Dalum et al., 1996; Hartley et al., 1993; Bretscher and 
Cohn, 1970), although the vast majority of B cells with receptors to self-proteins is removed by 
clonal deletion to induce tolerance to self and avoid autoimmunity  (Hertz and Nemazee, 
1998). These self-reacting B cells therefore internalise vaccine antigens, process and present 
the epitopes bound to HLA class II molecules. Among these is the foreign Th-epitope. 
Concurrently, APC also process the vaccine protein, and a subpopulation of Th-cells of the 
immune system respond by identifying the antigen as foreign, because of the inserted epitope. 
The Th-cells activated by this epitope provide help to the B cells presenting the same Th-
epitope on their surface. In this way, B-cells producing antibodies react, not only against the 
injected modified antigen, but also against the corresponding non-modified pathogenic self-
antigens which are activated and thereby proliferate  (Dalum et al., 1996).  
After the Th-cell-dependent activation, B-cells further increase the diversity and improve the 
affinity of their antigen receptors by rounds of mutation and selection in the germinal centre, 
resulting in high-affinity memory B-cells and antibody secreting plasma cells. After boosting 
with additional recombinant protein, this process is repeated, thereby enhancing the immune 
response  (Han et al., 1996; Hikida et al., 1996).  
Importantly, it has been demonstrated that the immunological process driving the cross-
reactive antibody response against the self-antigen only occurs in the presence of the modified 
self-antigens, and frequent re-immunisations are needed to maintain a high antibody titer. 
When the vaccine injections are discontinued, the antibody concentration decreases, thereby 
eliminating the risk of inducing a permanent autoimmune response  (Dalum et al., 1999).  
PADRE – a highly immunogenetic and promiscuous Th-epitope 
As explained above, helper T lymphocyte responses play an important role in the induction of 
both humoral and cellular immune responses. However, a lack of consistent help from T-cells 
can be a problem for generating general effective Th-cell responses, due to the extensive 
polymorphism of HLA molecules in the general human population, on which the peptide must 
bind. Therefore, the quality of the Th-cell epitopes is a crucial component of any vaccine. In 
Pharmexa’s vaccine approach, the Th-cell epitope is genetically added to the target molecule 
which therefore has the advantage that the most effective and polymorph epitope can be 
chosen among both natural and synthetic epitopes. 
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HLA II molecules present epitopes to Th-cells; however, there are several HLA II alleles in the 
human population, displaying extensive polymorphism in the domains responsible for antigen 
binding and interactions with the variable regions of the T-cell receptors. This polymorphism 
is also effecting epitope selection and presentation  (Corzo et al., 1995). Initially, the two 
universal P2 and P30 Th- cell epitopes of tetanus toxin were used, as epitope inserts. They 
bind several different HLA II molecules, and together they have a binding frequency of 
approximately 80% in the human population, individually P2 and P30 binds 56 % and 66%, 
respectively  (Panina-Bordignon et al., 1989). The P2 epitope comprises 14 aa and the P30 
epitope comprises 21 aa. Therefore, insertion both these epitopes is a rather large intervention 
in the target protein and one smaller universal epitope would be preferable. 
There are many instances, as the P2 and P30, in which a given peptide has been shown to 
bind to more than one HLA specificity, giving rise to so-called promiscuous epitopes. However, 
no naturally occurring epitopes are completely universal in binding all HLA molecules. For 
this reason, Pan DR helper T cell epitopes (PADRE) was constructed to bind most common 
HLA II molecules with high affinity and act as a strong immunogen (van Bleek and 
Nathenson, 1990). By sequencing of pools of naturally processed peptides, as well as structural 
analysis of individual epitopes, there was found an indication of the presence of two or more 
anchor residues required for binding to the HLA II. The PADRE peptide was engineered by 
introducing anchor residues for different motifs of the HLA-DR alleles within a poly-alanine 
backbone, and subsequent testing of the resulting peptides for their binding capacity to HLA 
II molecules. Because of the small methyl group exposed to for T-cell recognition, these poly-
alanine peptides were poor immunogens, but effective blockers of DR- restricted antigen 
presentation. By introducing bulky and charged residues at positions accessible for T-cell 
recognition a highly immunogenic epitope was obtained (Alexander et al., 1994).  
The PADRE peptide consists of the amino acid sequence AKFVAAWTLKAA and is able to bind 
with high or intermediate affinity to 15 of the 16 most common HLA types (Alexander et al., 
1994). It also binds most different haplotypes in mice, which is important when conducting 
pre-clinical investigations in this species. Further, when PADRE was evaluated for 
immunogenicity using human peripheral blood mononuclear cells in a proliferation assay, it 
was found to be approximately 100-fold more potent on a molar basis than a control tetanus 
toxoid-derived universal epitope. Because of its binding efficiency and promiscuity, PADRE 
should overcome the problems posed by the large polymorphism in the human population. 
Active vaccination - an alternative to monoclonal antibody therapy 
Therapeutic vaccination can be compared to treatment with monoclonal antibodies (mAb). 
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Like monoclonal antibodies, a vaccine technology is not limited to only one product or only one 
disease. In principle it can be used to target any self-protein associated with human chronic 
disease caused by or associated with over-production of certain proteins in the patients. 
The protein vaccine is injected subcutaneously or intramuscularly in an appropriate adjuvant 
formulation. Pharmexa expects that the treatment regimen for humans eventually will involve 
a small number of initial injections followed by regular booster injections every 3-6 months. 
Since a vaccine activates the patient’s own immune system to produce the antibodies, the dose 
of protein will be up to 50,000 times less per injection, compared to monoclonal antibody 
treatment. This results in less strain to the patient, as well as being considerably cheaper and 
probably a more effective treatment. Also, the principal adverse effect of monoclonal 
antibodies, namely, an immune reaction against the exogenous drug is not present in the 
vaccine strategy, since such a response is the basis for and desired effect of treatment. 
However, the injected protein can perform its natural function and therefore leads to an even 
more elevated level of the harmful effect; thus, it is of great importance to consider this issue, 
and if necessary, to inactivate the vaccine molecule through specific mutagenesis. 
 
In vivo data from AutoVac vaccines  
The first therapeutic vaccine developed by Pharmexa was an anti-TNF-α molecule. Although 
there are a number of cytokines in the proinflammatory immune pathways, inhibition of TNF-
α has a more universal effect on inflammation than the blocking of other cytokines. TNF-α 
inhibition improves several inflammatory conditions, and can ameliorate the destruction 
associated with inflammatory arthritis and the 
granulomatous diseases as Crohn's disease 
(Dinarello, 2000).  
There are presently comparable drugs avalible 
(Figure 2). Two TNF-α mABs have been developed 
and a TNF-α decoy receptor: Infliximab (Lochs et 
al., 1999) and Adalimumab (Machold and Smolen, 
2003). Infliximab binds to TNF-α and TNF-β and 
lyses TNF-producing cells to neutralise their 
activity. Adalimumab is a monoclonal fully 
human anti-TNF-α antibody binding with high 
affinity to TNF-α. By replacing murine with 
human elements, the production of antibodies 
that neutralise the Adalimumab injections is 
 Figure 2. Action of Biological TNF-α drugs. 
Inflammation occurs when the immune system 
attacks the patient’s own cells. Inhibiting the 
action of TNF-α can reduce this state. Two types 
of biological treatment are available; monoclonal 
antibodies and decoy TNF-α receptors. An anti-
TNF-α vaccine will resemble the action of mABs, 
but will bind at several positions of the target 
molecule due to the polyclonal nature of the 
response. (Illustration from the webpage of Gigt 
foreningen, www.gigtforenigen.dk) 
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reduced. Also, a soluble TNF-α receptor (Etanercept) is in use (Leonardi et al., 2003). It 
functions as a decoy receptor and thereby inhibits the signal transduction pathway of TNF-α. 
The ability of Pharmexas TNF-α vaccine to induce neutralising antibodies was tested in a 
mouse model of rheumatoid arthritis (Figure 3) (Dalum et al., 1999). The data show that 
vaccination not only reduces signs and symptoms of arthritis, but also significally reduces the 
incidence of the disease. Furthermore, an anti-TNF-α immune response could be maintained 
for an extended period of time, but if immunitions are discontinued, this response declines. 
Other AutoVac vaccines have been tested in animal models as RANKL against osteoporosis 
(Juji et al., 2002) and Her-2 against cancer with successful results (Renard et al., 2003). Her-2 
is currently tested in clinical trails in breast cancer patients. 
  
Figure 3. Immunisation with murine TNF-α vaccine molecules. 
Groups of 29 mice immunised with murine TNF-α vaccine molecules (o) or placebo (•) and boosted 3 
times at 2 weeks intervals. One week after last immunisation mice were immunised intradermally 
with bovine collagen to induce arthritis. A) Incidence of disease onset, B) clinical score C) swelling of 
the first affected limb, and D) the number of effected limbs E) level of TNF-α antibodies were 
measured after immunisation with CFA Complete Freunds adjuvant (•) or ISA51, an adjuvant 
approved for humans containing a mix of mineral oils and emulsifiers (o). Figures from Dalum et al. 
1999 
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A novel approach for generation of vaccine candidate molecules 
From an immunological point of view, it is of vital importance to retain the structural 
conformation of the target protein after introduction of the Th-cell epitope. Therefore, the most 
relevant requirement of the protein vaccine is that the insertion of the epitope does not disturb 
the three dimensional structure of the protein, because the immunogenicity and the 
conformation of the protein, and thereby its conservation of structural B-cell epitopes, are 
most likely are correlated. Thus, to acquire an effective neutralising antibody response, a high 
structural identity between vaccine molecule and native target protein is essential (Barlow et 
al., 1986). 
However, the insertion of the epitope is not a trivial task. A 12-30 amino acids peptide has to 
be accommodated in the protein sequence of the target molecule without disturbing the overall 
three dimensional structure. This modification often leads to a misfolding of the protein, and 
many different insertion sites have to be tried before a folding competent molecule is found.  
Today at Pharmexa the introduction of the epitopes is based on a search for areas or points in 
the target protein capable of accommodating the insertion based on rational design and 
serendipity. In brief, design of a vaccine candidate is largely based on the three-dimensional 
structure of the target protein when available. By studying the target protein and comparing 
it to homologous protein structures, suggestions can be made to where insertion of an epitope 
seems reasonable. Linkers between protein domains or loops connecting secondary structure 
elements as well as N- and C- terminals are the primary choices of insertion sites. Also, the 
computational folding prediction algorithms can be applied in the search. However, the 
calculation of such a large modification requires extensively large algorithms, and many of the 
variations in sequences and the stability of their conformations are distinguished only by 
relatively small energy differences. Furthermore, the effect of chaperones and other biological 
factors decisive for folding is difficult to include. Thus, it is difficult to make an accurate 
prediction of the structure and folding ability that is a consequence of insertion of the epitope. 
This leads to the construction of a significant number of variants by site-directed insertional 
mutagenesis and subsequent screening of these variants on the basis of expression capability. 
Therefore, a selection system for folded proteins among an extended library of variants with 
randomly inserted epitopes will be a valuable tool in the quest for finding potential vaccine 
molecules.  
General overview over the presented system  
The work presented here enables a search for permissive insertion sites in the target protein 
by a random approach, in other words; try out all - or many - possibilities. This not only 
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excludes the many unsuccessful insertions, but also identifies permissive sites that could not 
be predicted on the basis of current structural or functional knowledge of the protein. When 
using rational design the loops often are the target for epitope insertion. PADRE, the epitope 
used in the AutoVac molecules, is very susceptible to proteases (unpublished data from 
Pharmexa); therefore, the screen will be an advantage since it might enable insertion onto 
buried regions of the target molecule (Sheridan et al., 2002). Furthermore, it is an empirical 
system; no functional assay or beforehand knowledge of the target molecule structure or 
biological function is required. Therefore, the approach can be applied to non-characterised 
proteins for which no rational design approach is available. 
The system for variant generation- and selection system is designed in the following way; 
(Figure 4); i) a transposon-based mutagenesis procedure is used to generate a unique 
restriction site in the cDNA at random into which a sequence coding for an epitope is situated, 
thereby creating a library of putative AutoVac candidates; ii) the library is fused to the N-
terminal of the invertase protein and the fusion product is linked to the Cpy signal sequence 
directing the chimera to the secretory pathway; iii) the plasmids encoding the fusion protein 
are transformed into Sz. pombe; iv) the transformed cells are plated on selective media. 
Transformants expressing folding competent variants are selected, as only cells with invertase 
activity can utilise sucrose as carbon source and therefore grow. Hereby are foldable sequences 
are selected among millions of yeast transformants.  
 Considerations before making an exhaustive library 
To make an exhaustive library, compromising insertions at all positions in the amino acid 
sequence, the creation of double strand break at random in the encoding DNA is needed. 
Traditionally, this has been achieved by DNase1 digestion (Heffron et al., 1978) or chemical 
induced disruption (Murakami et al., 2002). However, these techniques have the disadvantage 
of being quite difficult to manage and require titration for each target. Furthermore, they 
Figure 4. Principle of the complete Selection System for foldable AutoVac proteins 
A Th-cell epitope (purple) is introduced into a target cDNA (blue) at random, making an insertional 
library. The library is subjected to selection in Sz. pombe where folding competent variants fused to the 
invertase marker supports growth on selective media. The sequence of the selected variants can then be 
analysed for epitope insertion sites. 
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produce breaking point hot spots, and are therefore not completely random. DNase1 and 
chemical disruption may introduce arbitrary deletions at the site of the cut. 
More recently, in vitro transposon has been used as a simple and rapid method to make 
random modifications in double-stranded DNA (Hayes and Hallet, 2000). In order to function 
in this context, it is important that 
the system used readily yield large 
numbers of independent, random, 
and simple insertions into any DNA 
target of choice. Another important 
attribute is its easy handling of the 
transposase and the transposon 
substrate. A comparison of the 
randomness of DNase1 cleavage, 
chemical cleavage, and transposon 
insertion can be viewed in figure 5. 
Briefly, figure 5A shows the 
distribution of double strand breaks 
in the GFP gene. A linker labelled 
with fluorecein has been attached to 
the 5´end of the sense DNA strand 
after the gene has been disrupted 
by either with Ce (IV)-EDTA 
treatment or DNAse 1 digestion. To 
map the distribution of double 
strand breaks formed by the two 
different agents the resulting DNA samples were analysed for size distribution on a high 
resolution PAGE (Murakami et al, 2002). As a comparison, shown in figure 5B, the insertion of 
transposon in the pBC plasmid has been presented. Here, the randomness has been 
investigated by a PCR based assay  (Haapa et al., 1999). As seen, the chemical cleavage is 
more random than the DNase1 generated where a very high degree of hotspots is seen. 
However, the transposon-generated insertions are more evenly distributed, and even though 
there are differences in the intensities of the single bands, insertions are found between all 
phosphodiester bonds.  
 
 
 
Figure 5. Distribution of double strand breaks: Comparison of the 
randomness of DNase1 cleavage, Chemical cleavage, and transposon 
insertion of fluorescence labelled DNA fragments 
A. Ce (IV)-EDTA or DNase1 Cleavage. A rather large degree of 
hotspots is displayed. Figure from Murakami et al, 2002. 
B. MuA transposon. All positions are represented, but some in a 
higher degree than others. Figure from Haapa el at, 2002. 
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Current systems for making insertional libraries 
A method for generation of an insertion library has been reported recently (Murakami et al., 
2002). This method, termed random insertion/deletion mutagenesis (RID), is based on Cerium 
(IV) as oxidative cleavage agent to generate the double strand breaks in the DNA fragment of 
interest. The method is a complex procedure requiring 9 reaction steps to complete 
construction of the library, including a PCR reaction that will generate unwanted errors in the 
insertional sequence. Ce (IV) is not completely random and multiple cuts in each fragment are 
difficult to avoid. Furthermore, the result showed that not all the insertions were as 
anticipated, in that additional bases had been deleted probably during treatment by the 
Klenow fragment. 
The random insertion of a transposon and a subsequent excision of most of the transposon 
sequence resulting in a characteristic 5 amino acid insertion has been published by several 
research groups (Hayes and Hallet, 2000). The 5 amino acids are composed of residues left 
from the transposon and a target sequence duplicated during the transposition reaction. This 
pentapeptide scanning mutagenesis of cloned target protein has proved a powerful method for 
dissecting protein activity and function.  
A transposon-based approach inserting a specific DNA sequence into a target protein at 
random has been described (Sheridan et al., 2002). This approach was used for finding 
insertion sites that can accommodate green florescent protein (GFP) without destroying the 
biological activity of a given protein. The glutamate receptor subunit, GluR1, and a G protein 
subunit were used as model proteins for this approach. Some of the proteins retained their 
signalling function after insertion, and the random nature of the transposition process 
revealed permissive sites for insertion that one would not have been predicted on the basis of 
structural or functional models of how that protein works. 
Current in vivo screens for folding-capability 
Different assays for detection of soluble recombinant proteins have been developed in E. coli. 
It is known that misfolding leads to redistribution of proteins to the insoluble fraction in the 
cell due to aggregation. Therefore, folding of a protein of interest can be detected by creating 
hybrid proteins comprising the protein of interest fused to the N-terminal of a reportable 
protein. If the N-terminally protein moiety is soluble, the fused reporter protein domain leads 
to the reportable phenotype. In contrast, aggregation and inclusion body formation of the N-
terminal moiety result in the relocation of the reporter to the insoluble protein fraction in the 
cells, and the reportable phenotype is not displayed.  
The first of these screens was made by expressing proteins fused to chloramphenicol acetyl-
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transferase (CAT) fused to HIV integrase (Maxwell et al., 1999). An insoluble protein 
exhibited a decreased resistance to chloramphenicol, compared to fusions with soluble 
proteins. Further, a soluble mutant of an insoluble mutant of HIV integrase could be selected 
from a pool of un-soluble wild-type protein by plating on high levels of chloramphenicol. No 
actual selection experiments on a random mutagenised gene were preformed. This system 
contains the useful feature of having an amber codon between the gene of interest and the 
reporter gene. This gives the possibility to express protein without the CAT moiety, merely by 
changing expression strain, without additive cloning procedures after the selection scheme. 
The basis of another assay is structural complementation of the α- and Ω- fragments of β-
galactosidase (Wigley et al., 2001). Fusions of the α-fragment to the C-terminus of the 
Alzheimer's amyloid β peptide and a non-amyloidogenic mutant, revealed a clear correlation 
between β-gal activity and the solubility/folding of the target. Additionally, the assay was 
tested using different proteins widely varying in solubility levels fused to the α-fragment, 
displaying β-gal activity correlating to their solubility. This assay is solely a screening system 
- no selection is included.  
Also, a screening system based on GFP fluorescence has been described (Waldo et al., 1999). 
Here GFP is used as indicator of protein folding, when fused to a panel of 20 different 
proteins. The fluorescence of E. coli cells expressing the GFP fusions is shown to be related to 
the productive folding of the N-terminal protein domains expressed alone. This system was 
used to evolve proteins, normally prone to aggregation during expression in E. coli into closely 
related proteins that fold robustly and are fully soluble and functional.  
Two eucaryotic screening systems for protein folding have recently been developed. Both 
screening methods are based on the quality-control system of the yeast secretory pathway that 
is demonstrated to prevent the release of misfolded or incompletely folded proteins (Ellgaard 
and Helenius, 2003). In the first method the secreted proteins are displayed on S. cerevisiae 
cell surface receptors, labelled with antibodies, and quantified by flow cytometric analysis. 
This procedure was used for identification of protein with high stability and secretion 
properties among a library of random single site mutations (Boder and Wittrup, 2000; Boder 
and Wittrup, 1997). However, this system is based on fluorescence-activated sorting (FACS) 
and requires the availability of this expensive instrument and also antibodies specific for the 
target.  
In the other method, a cellular screening is combined with a small, generic tag for antibody 
detection. This system was used to screen a library of random mutants of an unstable variant 
of bovine pancreatic trypsin inhibitor (BPTI). 3 mutants with improved folding properties 
were found. However, the screen uncovered many false positives, so subsequent use of a liquid-
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culture secretion screen and a gel electrophoresis assay, were needed to eliminate false-
positive mutants. Further, in this type of assay, based on antibody detection of positive 
colonies, there is no selection of positives included in the scheme (Hagihara and Kim, 2002).  
Considerations prior to development of the selection system 
The main difference between a screen and a selection procedure is that in a screen all the 
members of a population must be examined. Accordingly, screens are not as effective as 
selections because fewer individuals can be examined. However, screens can be useful because 
they allow the detection of a broad dynamic range of the investigated activity, whereas 
selection provides a positive/negative conclusion. In this study the interest is to select for 
folded sequences among a library of variants. Therefore, in principle the answer is simply if 
the molecule can fold or not. Consequently, a selection procedure is the most appropriate to 
the task. 
It has been proven in the different vaccine projects at Pharmexa, as well as in other 
laboratories around the world, that human proteins can be difficult to express in E. coli, with 
aggregation of improper folded proteins as a consequence (Baneyx and Mujacic, 2004). This 
can be due to many factors, but especially the difference in transcription, folding (chaperones 
and other foldases), and secretions system in pro- and eucaryotes may be limiting. The 
probability of a successful expression of eucaryotic proteins is considered better if a eucaryotic 
host cell is used. Moreover, E. coli lacks the ability of post-translational modifications of the 
eukaryotic cells that can be important for recognition by the immune system (Makrides, 1996). 
Therefore, it was an initial perquisite of the presented project that the system developed was 
in a eucaryotic host. However, the existing eucaryotic systems were found to be inadequate for 
the task due to the drawback described above. 
The screening and selection system is based on the knowledge that proteins folding up 
correctly in the ER is exported, whereas, insoluble protein variants are sent to the proteasome 
for degradation. The mechanism of ER dependent degradation of misfolded proteins is not 
completely elucidated. That these aberrant products, however, are not exported to the surface 
of the cell is well-established (Helenius et al., 1992). It is a fair assumption that if one domain 
of a protein, especially the N-terminal domain, is not folded correctly, the protein is not 
exported and does not reach the cell wall.  
Sz. pombe was chosen as host for the screening /selection system since; it resembles higher 
eucaryotes in the structure and function of genes, proteins and processing of RNA and 
proteins. The primary components of the selection system are Carboxy-peptidase Y (Cpy) and 
invertase genes and their products, as this system is based on the redistribution of a hybrid 
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protein, as are the described E. coli selection systems. These proteins have been the primary 
substrates for the investigation of the secretion pathway in yeast; both S. Cerevisiae and Sz. 
pombe, so their behaviour is known in detail (Figure 6). The Sz. pombe Cpy signal sequence 
has been shown to support secretion in Sz. pombe, both of invertase (Tabuchi et al., 1997), and 
TNF-α (Kjaerulff and Jensen, 2005). The invertase protein has the enzymatic activity of 
hydrolysing sucrose to glucose and fructose, thus only yeast having invertase activity can be 
grown on sucrose media. Moreover, since protein stability/folding is expected to correlate with 
secretion of the invertase enzyme (Kowalski et al., 1998), which in turn correlates with cell 
growth on sucrose media, growth should likewise correlate with folding. 
This technique should greatly accelerate the discovery of functional vaccine proteins. This 
approach does not require functional assays for the protein of interest and provides a simple 
route to find folding competent proteins. It is possible, in a screen based on folding 
competence, that positive candidates are folded in a manner not resembling the wild-type 
protein. However, since the majority of the primary sequence resembles the wild-type target 
molecule, the innate folding preference most likely also bears a resemblance to this. 
 
 
Figure 6. Delineation of the selection system 
The gene of interest (Blue) is fused to a selectable genetic marker invertase (Red), and the Cpy signal sequence 
(Green). Thereby, proteins variants will be directed to the secretory pathway along with the detectable 
reporter. After translation, the variants go through the secretory pathway passing cell organelles, including 
endo-plasmic reticulum (Green) and Golgi apparatus. In these organelles the proteins are correctly folded and 
disulphide linkage and glycosylations are formed. After the posttranslational events, correctly folded proteins 
are secreted, whereas misfolded proteins are retained and degraded within the cells proteasome (Purple). This 
means that only colonies containing the genetic sequence for a folding competent protein variant will be able to 
survive on sucrose plates. 
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 Random insertion of epitopes using genetically modified transposons.  
In order to make use of the selection and screening scheme, a library of vaccine variants with 
randomly introduced epitope needs to be generated. The primary requirement for creating 
such a library is randomness of the epitope insertion. Thus, a straightforward and efficient 
technique for generating a random double-strand break in the cDNA sequence is needed. In 
vitro transposition using genetically modified bacteriophage Mu mini-transposons fulfilled 
this criterion. The rapid and random nature of the transposition process makes it possible to 
generate many different vaccine variants to be screened in the folding assay. 
Biology of transposons 
Transposons are discrete mobile DNA segments able to insert into non-homologous target 
sites. They are ubiquitous and many different transposons have been isolated on DNA level 
from all known organisms - more than 500 in bacteria alone (Mahillon and Chandler, 1998). 
They have been regarded as selfish DNA elements living within the genome of cellular 
organisms, usually conferring no selective advantage to the host and in this manner similar to 
viruses. This, however, is not a completely adequate description. For example, in bacteria the 
antibiotic resistance genes and colicin genes confer a synergistically beneficial effect for both 
host and element. Indeed, the host cell acquires an advantage to survive exposure to hostile 
environmental factors, and the transposable element achieves an enhanced copy 
multiplication and the opportunity to spread to other hosts as a consequence of beneficial 
effect. Also, recent data suggest that the transposons have some valuable effect on the 
eucaryotic host since transposons may have been adopted into the vertebrate immune system 
as a way of generating antibody diversity. This notion is implicated by the fact that the V (D)J 
recombination system operates by similar mechanisms as transposons (Agrawal et al., 1998; 
Zhou et al., 2004). Another, profound biological effect is shown by transposons being involved 
in many different processes in genome alteration including element insertion and deletion, 
homologous recombination between element copies, and horizontal gene transfer. Further, 
transposons are now known to be a major component of repetitive sequences of all 
characterized eukaryotic genomes and a major cause of genomic expansion in eucaryotes 
(Lander et al., 2001) – in mammals they account for nearly half of the genome. These events 
may not be beneficial to the individual host cell, but is driver of evolution contributing to a 
wider diversity of a population. 
Among the phages of gram-negative bacteria, bacteriophage Mu is the most efficient 
transposon known. The genome of bacteriophage Mu is a transposon using transposition both 
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to integrate into the DNA of a new host cell and to replicate before phage induced lysis 
(Mizuuchi, 1992; Lavoie and Chaconas, 1996). When injected into the host cell, the phage DNA 
is integrated at a random site of the host genome by the phage-encoded transposition 
apparatus. Although the initial integration event does not involve replication of Mu, lytic 
development involves many replicative transposition events exploiting the host replication 
apparatus to form multiple integrated copies of Mu.  
Functional features of DNA and protein elements of transposons 
Transposition reactions occur in large catalytic protein-DNA complexes called transposomes. 
These contain the DNA substrate, oligomers of the transposase, and accessory proteins and 
involve multiple protein-protein and protein-DNA interactions. The assembly of the 
transposome is likely to be a key regulator part of the transposition, since it can assure that 
the appropriate substrates, being the terminal ends of the transposon, and sometimes the 
target is present as well, and hereby promotes coordination of the reaction steps. 
The majority of the transposons is characterized by terminal inverted repeat (ITR) sequences 
of 10 –40 bp, flanking an internal transposon sequence encoding at least a transposase 
catalysing the transposition reaction, and frequently additional proteins (Mahillon and 
Chandler, 1998). In Mu, and most other transposons, two functional domains are found in the 
ITRs, both of them required for transposition. One region, counting the 3’ terminal 5’-CA bp, is 
involved in the cleavages and strand transfer in the strand transfer reaction. The other region 
has multiple and asymmetrical sites implicated in binding the transposase, the enzyme 
catalysing a transfer. In Mu there are three recognition sites, distinct from the cleavage sites, 
sharing a 22-base pair consensus sequence (Craigie et al., 1984). The sites are referred to as 
R1, R2, and R3 for the right end and accordingly, L1, L2, and L3 for the left end (Kuo et al., 
1991; Craigie et al., 1984). The internal part of the transposons are genetically compact, and 
usually encode no functions other than those involved in their mobility, though the antibiotic 
resistance and colicin genes are notable exceptions. The most important gene encodes the 
transposase, in Mu called MuA. In the DNA, flanking the transposon DNA element, there are 
always two direct repeats. These sequences are not an actual component of the transposon and 
are not included in the sequence of the moving element when jumping to a new target. The 
direct target repeat is always a duplication of a fixed length characteristic for a given element. 
In Mu the length is 5 bp, other elements have various lengths between 2 and 14 bp (Mahillon 
and Chandler, 1998). 
The most important protein, which in some transposons is the only encoded protein, is the 
transposase. All transposases that have been investigated have a common significant three-
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dimensional structure. The protein is comprised of two functionally distinct domains: N-
terminally, a sequence specific DNA binding domain for recognition of the ITRs (Nakayama et 
al., 1987), and C-terminally, the catalytic core domain, containing the protein's active site with 
an invariant structural triad D,D35,E-motif (Asp, Asp, 35 aa spacer, Glu), responsible for the 
DNA cleavage (Rice and Mizuuchi, 1995). Both the recognition sequences and the 5'-CA 
cleavage sequences are required for transposition (Baker and Mizuuchi, 1992). This domain 
organisation is a general feature of most transposases and is also shared by the recombinases 
responsible for integration of the HIV virus (Yang and Steitz, 1995) and immunoglobulin 
reassembly (Agrawal et al., 1998). 
Transposases are able to form multimeric complexes essential to their function (Polard and 
Chandler, 1995). MuA forms a tetramer (Figure 7), where three subunits tightly bind the R1, 
R2, and L1 sites, the fourth is weakly associated to the L2 site but, in contrast, have a strong 
interaction to other subunits in the complex. At least two of the four MuA subunits 
individually bridge the transposon ends; the subunit bound to the R1 connect to the left 3’ AC 
cleavage site, and likewise the subunit bound to the L1 connect to the right 3’ AC cleavage site 
(Rice and Mizuuchi, 1995; Savilahti and Mizuuchi, 1996; Aldaz et al., 1996). This means that 
the active site of the MuA subunit bound at R1 promotes reactions in trans to the left 
transposon-end and vice versa. This is probably in order to coordinate the reaction at the two 
ITRs ensuring that DNA transposition always occurs properly, avoiding damage to the host 
genome by partially completed reactions. 
The number of other expressed transposon proteins varies considerably between the different 
types of transposons (Mahillon and Chandler, 1998). In the case of the Mu, the most critical 
ones are the phage encoded MuB, and the enhancer protein together with the host-encoded 
 
Figure 7. Model of transposome assembly 
Individual MuA monomers bind to the recognition sites of the transposon and form a stable tetramer, 
synapsing the ends and engaging the cleavage site. 
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protein HU and IHF. MuB is an ATP-dependent DNA-binding protein regulating the activity 
of MuA. It is involved in target selection and capture acting scaffold for transposome 
assembly, thus providing a preferential target for MuA transposase complexed with the ITR 
ends. MuB also functions as an allosteric activator of MuA, and displays an ATPase activity 
stimulated by DNA and MuA (Lavoie and Chaconas, 1996).  
The enhancer protein participates in the assembly of the MuA tetramer on the DNA and 
further functions as positive regulator of expression of the phage encoded transposition 
proteins (Lavoie and Chaconas, 1996). Recruitment of the DNA bending enzymes HU and IHF 
to a DNA site induces a bending in the super-coiled DNA required for transposase assembly in 
vivo. The HU binding site is the Mu spacer between the L1 and L2 transposase binding sites 
(Kobryn et al., 1999). These auxiliary factors have been shown dispensable for in vitro 
transposition, where MuA can work separately, still integrating transposons in target DNA 
(Mizuuchi, 1992; Lavoie and Chaconas, 1996). 
DNA transfer: The mechanism of reaction. 
The DNA transposition follows a common mechanism with some variations depending on the 
element (Mizuuchi, 1992; Mahillon and Chandler, 1998). The transposase is expressed and 
identifies the ITR within the donor DNA, by highly sequence specific protein-DNA 
interactions. After binding and multimerisation, the transposase catalyse a blunt double-
stranded break flanking the transposon. This is done by a nucleophile attack at the 5’ 
phosphate group in the DNA by a water molecule, to expose a free 3’ OH-group (Figure 8). The 
gapped donor DNA resulting from transposition is repaired by homologous recombination by 
the host cell repair apparatus (Hagemann and Craig, 1993). The transposase and transposon 
ends are now assembled into an enzyme complex, with an active 3’ OH-group at each end of 
the transposon. One strand of the transposon DNA attacks, again by nucleophile attack, the 
target through trans-esterification (Goldhaber-Gordon et al., 2003; Mizuuchi and Adzuma, 
1991). The target double-strand is now cleaved open by a staggered cut, where each end of the 
transposon DNA is joined to an overhanging end of the recipient DNA. The DNA polymerase 
completes insertion by repairing the short, overhanging sequences, resulting in a 
characteristic short direct repeat on each side of the transposon insertion in the recipient DNA 
(Bainton et al., 1991). Although the two reactions performed by the transposase are distinct, 
they are chemically related, both being one-step substitutions of the oxygen groups on a DNA 
phosphate  (Engelman et al., 1991; Mizuuchi and Adzuma, 1991). The major differences 
between the two reactions are the identity of the nucleophile and the identity of the phosphate 
at the reaction centre.  
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The transfer process results in loss of the 
transposon from the donor DNA and insertion of 
the transposon into a recipient DNA. So, the 
transposon is not duplicated in the process. But, 
because transposition often occurs after 
replication of the donor DNA molecule, it is not 
possible to determine if a transposon moves by a 
non-replicative mechanism by merely looking 
for loss of the transposon at the original site. 
Unique to the lytic part of the replication cycle 
of bacteriophage Mu and the Tn3 family of 
transposons, the DNA element remains 
attached to the donor DNA while inserting into 
the new target. In these cases a 3’ nicking 
reaction occurs at each transposon ends (rather 
than double strand breaks), thus the 5’ end of 
the element remains attached to the donor 
DNA. The exposed 3’ end then joins the target 
DNA. This transposition reaction is followed by 
DNA replication. This generates two copies of 
the element in a structure called a cointegrate in which the donor and target backbone are 
connected by directly repeated copies of the transposon at each junction (Mizuuchi, 1992). This 
structure is subsequently resolved by recombination between the two copies of the element. 
Target site selectivity and Target site immunity 
Some transposons exhibit essentially random patterns of insertion, whereas others have 
considerable target site selectivity. The selectivity can result both from the quality of the DNA 
such as silenced DNA, or promoter regions, or can be a preferred consensus sequence of 
varying stringency. Mu has low target site specificity and shows a very random distribution 
and can transpose to essentially any DNA sequence, although it exhibits a relative preference 
for the degenerate sequence Y (G/C)R (Mizuuchi and Mizuuchi, 1993). It has been reported 
that Mu displays a dramatic preference for insertion into mismatched DNA sites (Yanagihara 
and Mizuuchi, 2002) 
The bacterial transposons Mu, Tn3 and Tn7 are known to exhibit target immunity, a process 
that prevents the element from transposing into target DNAs already containing a copy of the 
 
 Figure 8. Schematic representation of the trans-
position mechanism.  
Transposomes mediate two sequential chemical 
reactions, when transferring the transposon DNA 
from one site to another: (i) DNA cleavage, in 
which a nick is introduced precisely at the end of 
the transposon, on the 3' strand and (ii) DNA 
strand transfer, in which the nicked strand is 
joined to a separate target molecule. Figure from 
Mizuuchi et al, 1991. 
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transposon (Robinson et al., 1977). This immunity can have two biological functions. One is to 
ensure a spreading of the transposons to as many different DNA units as possible, promoting 
the distribution and survival of the transposon. Another is to prevent the destruction of one 
transposon by the integration of another. The presence of a transposon end in a target DNA 
reduces the frequency of a second transposon event with 100-1000 fold in vivo, and it has been 
shown that the Tn7 element can inhibit insertion of a second element over a distance of 190 kb 
to (DeBoy and Craig, 1996). Transposition into other DNA molecules is not inhibited, so target 
immunity is a cis-acting effect, not a global trans-inhibition. Analysis using plasmid targets 
shows that the signal for the inhibition lies within the ITR sequences (Adzuma and Mizuuchi, 
1989; Darzins et al., 1988; Hauer and Shapiro, 1984; Lee et al., 1983) and is transmitted by 
the MuB protein via the MuA. Interaction of MuB with MuA bound to the recognition 
sequences in the ITRs of the transposon provokes ATP hydrolysis by MuB following a release 
of MuB from the target DNA. This in turn reduces the ability for the DNA to function as a 
target, and the MuB is redistributed to those DNA molecules not containing a transposon 
element (Adzuma and Mizuuchi, 1991).  
Insertion mutagenesis with a heterologous transposon  
The development of in vitro transposition systems has been based on experiments showing 
that it is possible to construct artificial mini-transposons with the only requirement being that 
of containing some of the transposase binding sites of the ITRs and the catalytic 3’ terminal 
base pairs (Savilahti et al., 1995). Furthermore, some systems exploit the fact that 
transposition in vitro is possible using only the transposase and in absence of other protein 
factors (Hayes and Hallet, 2000). In principle, any DNA fragment flanked by the trimmed 
terminal inverted repeats can be used as a mini-transposon and the core sequence of the 
transposon is totally open to genetic manipulation.  
As described above most transposons function similarly, and a number of analogous systems 
has been developed based on different transposons as tools for biotechnological applications in 
insertional and truncation mutagenesis. These include Ty1 from yeast, MoMLV retroviral 
integrase (Singh et al., 1997), the mariner element Himar1 (Lampe et al., 1999; Akerley et al., 
1998) from the horn fly and Tn7 (Biery et al., 2000a; Biery et al., 2000b) and Tn5 (Goryshin 
and Reznikoff, 1998), Tn552 (Griffin et al., 1999), and Mu (Haapa et al., 1999) of bacterial 
origin. Several are commercially available; however, if necessary, the components are readily 
produced by standard laboratory techniques. Tn7 demonstrates high transposition efficiency, 
and target immunity. However, Tn7 has long, complex ends impeding the construction of 
alternative transposon derivatives. Additionally, transposition requires three proteins and a 
two-step reaction. Normally, Tn7 shows a very high degree of target specificity; however, the 
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version used for mutagenesis or sequencing exploits a mutant of the TnsC protein (a factor 
analogue to MuB) with a relatively little target specificity. The Ty1 insertion, although 
essentially random, shows quite low efficiency and needs a relatively large quantity of both 
transposon and target DNA. In the Tn552, Tn5, and Mu systems, all employing a linear 
modified version of the transposon, efficient strand transfer has been obtained with purified 
transposase, facilitating the generation of very large numbers of independent insertions in a 
single reaction. Furthermore, the transposon ends have a sufficient degree of plasticity to 
enable genetic engineering and artificially introduce restriction enzyme recognition sequences 
close to both ends in ITRs. This allows most of the transposon DNA sequence to be removed, 
subsequently leaving only a small sequence of the transposon, plus the duplication of the 
target sequence.  
Since the Mu based systems appear equally simple, efficient, and random, the different 
artificial restriction enzyme recognition sites introduced at the ITR ends have been the 
decisive factor in the choice. In the Mu system, the Not1 restriction enzyme fitted the PADRE 
insertion sequence so well that only two additional amino acids were present after insertion. 
Furthermore, the target selectivity for Mu in vitro transposons is the best studied, and has 
proven to be effectively random (Haapa et al., 1999). The method exploits the properties of a 
mini-Mu transposon and uses only the MuA transposase. The accessory protein and DNA 
cofactors from the host cell and from the original phage transposon involved in and controlling 
the Mu transposition are not included (Mizuuchi, 1992). The in vitro Mu reaction differs from 
the authentic in vivo reaction, as the two-step process of cleavage and strand transfer is 
reduced to only the latter step. This is possible by using pre-cut donor DNA, thereby miming a 
`cut and paste’ type of transposition, and eliminating the need for the DNA bending factors 
and enhancer protein. The target preferences observed in vivo are most likely to be a result 
from the MuB protein, host factors, or features of gene expression. These factors are 
eliminated in vitro, resulting in a more uniform distribution of insertions (Haapa-Paananen et 
al., 2002). However, since target immunity is probably facilitated by the MuB protein, this 
cannot be expected in the in vitro reaction.  
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 Protein folding, quality control and secretion  
The screening assay established here is based on a sorting between folded and non-folded 
proteins in the secretion pathway and the resulting link between protein folding and protein 
secretion in eucaryotic cells. The current knowledge that forms the basis for this rationale is 
presented below.  
The intracellular compartments involved in secretion 
Many proteins, such as hormones and components of the extracellular matrix, must be 
directed to the cell surface and secreted. The secretion system is made up of separate 
organelles: The endoplasmic reticulum (ER), the Golgi complex, and the plasma membrane. 
Additionally, tubulovesicular transport elements mediate intracellular membrane transport 
between these organelles. Membrane interchange within this system flows along highly 
organized directional routes, balanced by retrieval pathways bringing membrane and selected 
proteins back to the compartment of origin (Cole and Lippincott-Schwartz, 1995) (Figure 9). 
The ER is an elaborate network, extending 
from the nuclear membrane throughout the 
cytoplasm, of inter-connected membrane-
enclosed tubules and layered flattened sacs 
(cisternae). It is the largest organelle of most 
eucaryotic cells representing about 10% of 
the total cell volume. There are two different 
types of ERs. One is the smooth ER that is 
not associated with ribosomes and is 
involved in metabolism of organelles, as lipid 
donation to other organelles, Ca+ 
homeostasis, and biogenesis of organelles 
take place here. Most notably in this context, 
is the rough ER covered by ribosomes on its 
outer surface. It is starting point for 
secretion, and functions in protein 
processing of secreted proteins. The protein 
concentration here is very high, more than 
100 mg/ml (Marquardt et al., 1993). In this 
gel like protein matrix, chaperones and 
folding enzymes are very abundant, greatly 
 
 
Figure 9. The intracellular compartments involved in 
secretion 
Proteins from the ER are transported to the cis Golgi 
network by ER derived vesicles that fuse and form the ER-
Golgi intermediate compartment (ERGIC). ER resident 
proteins that contain the KDEL retrieval signal are 
returned from the ERGIC and the cis Golgi network via 
the retrograde pathway. The medial and trans 
compartments of the Golgi stack are the sites of most 
protein modifications. Next, proteins are carried to the 
trans Golgi network, and sorted for transport to the 
plasma membrane, secretion, or lysosomes. Figure from 
Cooper,G.M 2000. The Cell: A Molecular Approach. 
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outnumbering the newly synthesised substrates. The ER is highly specialised for folding and 
secondary modifications of proteins. To carry out this function, the compartment has a unique 
high oxidising potential, allowing disulphide bond formation (Tu et al., 2000), a glycosylation 
apparatus, and a specialised subset of chaperones and other protein-modifying enzymes.  
The secretory proteins continue their journey towards the exterior, in small protein coated 
transport vesicles budding off from specialised exit sites on the ER, which are smooth 
ribosome-free sections (Palade, 1975). The vesicles fuse to form vesicular-tubular clusters and 
from here secretory proteins move on to the cis-Golgi reticulum and move by cisternal 
migration to the trans face of the Golgi, and next into the trans-Golgi reticulum, another 
complex network of vesicles. Here they are sorted and packaged into post-Golgi secretory 
vesicles moving through the cytoplasm to fuse with the cell surface while unloading their 
cargo (Hauri and Schweizer, 1992; Saraste and Kuismanen, 1992).  
Signal sequences directs membrane translocation  
The synthesis of all proteins starts in the cytosol; however, proteins destined for secretion are 
repositioned into the ER as an early event of translation. This targeting of nascent polypeptide 
chains are initiated by a signal peptide sequence (Keenan et al., 2001), directing secretory 
proteins to the membrane of the ER. There is not one universal signal, but generally, the 
signals are N-terminal extensions with a short N-terminal region, a hydrophobic core region, 
and a polar C-terminal. However, the signals can also be located within a protein, or at its C-
terminal end (Martoglio and Dobberstein, 1998). When comparing a large number of signal 
sequences a large variability is found in their relative size, ranging from 15-50 residues. The 
hydrophobic core consists of six to fifteen amino acids, and mutation analysis reveals that this 
is the most essential part required for ER-targeting and membrane translocation (von Heijne, 
1985). Flanking the hydrophobic region C-terminally are polar residues often containing a 
helix-breaking proline, glycine residues, and small-uncharged residues in position –1 and –3. 
The latter determines the cleavage site of a peptidase, fitting into a shallow depression in the 
signal peptidase (von Heijne, 1990). Several polar residues are often found at the N-terminal 
side of the hydrophobic region giving net positive charge. This region is the main contributor 
to the variation in the overall length of the signal sequence. Notably, different signals can be 
interchanged between proteins, even from different organisms and, nevertheless, follow the 
original targeting pathway (Martoglio and Dobberstein, 1998). This feature is widely used for 
recombinant expression of heterologous proteins, where a few common signal sequences are 
used to target any gene of interest for secretion. 
In the most common pathway in eukaryotes, co-translational translocation, a signal 
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recognition particle (SRP) identifies the hydrophobic segment of the signal peptide, just after 
emerging from the ribosome, and it binds the ribosome as well as the signal sequence (Matlack 
et al., 1998). Then the SRP arrests polypeptide chain elongation on the ribosome and the 
complex binds to the ER-bound SRP- receptor, attaching the ribosomes to the ER. SRP is 
released and the protein synthesis restarts into the protein translocation channel. This is a 
pore formed by the heterodimeric TRAM/Sec61 complex, through which the precursor protein 
is entering the ER lumen (Johnson and van Waes, 1999). After entry into the lumen the signal 
sequence is cleaved off the precursor protein by a membrane bound signal peptidase. Due to 
co-translational, the transport growing chain is never exposed to the cytosol and does not fold 
until it reaches the ER lumen. Thus, the protein crosses the membrane in an unfolded state 
and the co-translational translocation of growing polypeptide chains is driven directly by the 
process of protein synthesis.  
Protein folding in the ER 
Each newly synthesised chain of amino acids has to fold into a unique active conformation 
following its synthesis. For proteins crossing the ER membrane while translation is still in 
progress, the emerging protein immediately starts to fold when entering the lumen. The 
concurrent event of translocation across the ER membrane and folding permits a sequential 
folding, potentially improving the folding efficacy, particularly in multi-domain proteins 
(Netzer and Hartl, 1997b). As soon as enough amino acids extend beyond the ribosome, they 
will fold to the lowest available energy for that part of the chain. This will presumably involve 
the correct secondary structure, and in all probability an entire domain formation for larger 
multi-domain proteins, thereby minimising the error rate for complex proteins (Netzer and 
Hartl, 1997a). The correct tertiary sequence is acquired when the whole protein has been 
translocated. This is done by gradually combining and recombining secondary structures and 
single domains (Jaenicke, 1991). In this way protein folding is simplified by breaking it down 
into sequential steps. The N-terminal domains often seeds the folding of the subsequent parts 
of the proteins, hence directing and hastening the folding process (Netzer and Hartl, 1997a; 
Baldwin, 1989). 
Even though the native conformation of a protein lies encoded in its primary structure, the ER 
enhances protein-folding efficiency immensely. As in the ER lumen, a complex chaperone 
system has evolved to assist the folding process, by facilitating rate limiting steps, preventing 
aggregation by shielding the folding protein from unwanted intra-and inter molecular 
interactions, and preventing premature transport of unfolded proteins along the secretory 
pathway (Feldman and Frydman, 2000). The best studied are the Hsp70 chaperones BiP 
(Kar2p in yeast) (Gething and Sambrook, 1992) and Glucose-regulated protein 170 (GPR170) 
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(Spee et al., 1999), which recognises hydrophobic patches on proteins, and the lectin-like 
chaperones calnexin and calreticulin, which bind monoglucosylated N-glycans (Ellgaard and 
Frickel, 2003). In addition, other specific folding enzymes lower the activation energy required 
for processes as disulphide bond formation, by interaction with substrate proteins; this can be 
protein disulfide isomerase (PDI) and oxidoreductase ERp57 (Ruddock et al., 2000). Also, the 
oligosaccharyl transferase complex (OST) can carry out N-glycosylation.  
ER Quality control mechanisms  
The synthesis of defective proteins is a common phenomenon – it is estimated that as many as 
30% of newly synthesised proteins contain translational errors (Schubert et al., 2000). 
Therefore, a quality control system has evolved in the ER to function as a checkpoint for 
discriminating between properly folded proteins and terminally misfolded species, as well as 
unassembled protein subunits (Figure 10). At first, the misfolded polypeptides and orphan 
subunits are retained in the ER to undergo new attempts for folding. If this fails, they are 
subsequently subjected to elimination though ER-associated degradation (ERAD), a protective 
mechanism of vast importance for cell survival (Ellgaard and Helenius, 2003). The quality 
control seems to be based on folding ability alone and not on functionality. How the cell makes 
the conformational sorting is unclear, but most, if not all, chaperones and folding enzymes 
seem to contribute (Anken et al., 2005). Also, distinct systems seem to be employed for 
glycoproteins and non-glycoproteins. 
When chaperones are able to bind exposed hydrophobic stretches of a polypeptide, it means 
that the protein is not fully folded or assembled to a matching subunit. This retains the 
protein in the ER, even though the chaperone and immature protein go through cycles of 
binding and release. Analogues, unpaired cysteines cause PDI mediated retention (Anelli et 
al., 2003; Sitia et al., 1990). It is unclear how BiP and PDI decide whether an unfolded protein 
is a folding intermediate, or a terminal folding failure ripened for proteasome degradation. 
The majority of the secreted proteins is glycosylated. For glycoproteins in mammalian cells, 
the quality control system engages the action of calnexin and calreticulin (Ellgaard and 
Frickel, 2003), UDP Glc: glycoprotein glucosyltranferase (GT), and glucosidase II enzymes 
(Parodi, 2000). Here, GT serves as a folding sensor, since it glycosylates only misfolded or 
partly folded glycoproteins. Hydrophobic residues exposed near glycosylation sites in 
incompletely folded conformers mediate GT recognition. This structural feature is common to 
all non-native conformers (Caramelo et al., 2004). Also, an enhanced dynamic mobility of 
folding intermediates may play a part of the selectivity of GT (Ritter and Helenius, 2000). 
Proteins re-glycosylated by this factor have a prolonged association with calnexin and 
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calreticulin (Ritter et al., 2005). In yeast, there is no GT equivalent, but increasing evidence 
proposes that the Kar2p chaperone could play a similar role. Kar2p mutants are defective in 
ERAD and exhibit aggregation of misfolded proteins (Plemper et al., 1997). 
ERAD activity is partly regulated by the unfolded protein response (UPR)  (Casagrande et al., 
2000). The UPR is a signal transduction pathway connecting the ER and nucleus to monitor 
and respond to the changing needs of the early secretory pathway. In Saccharomyces 
cerevisiae, Ire1p, a transmembrane kinase localized to the ER/nuclear envelope, senses the 
concentration of unfolded proteins in the ER by a binding competition to Kar2p between the 
Ire1p lumenal domain and unfolded proteins. As a consequence of increasing amounts of 
unfolded proteins there is an exhaustion of unbound Kar2p molecules by sequestration, 
leading to the dimerisation of Ire1p. The dimerisation induces a conformational change 
transmitting a signal across the membrane, by activating a cytoplasmic kinase activity, and 
causing a splicing of the HAC1 mRNA, thereby allowing synthesis of the Hac1p transcription 
factor, which in turn, upregulates genes containing a UPR response element. This signal 
cascade leads to an increase in the level of proteins required for folding and quality control 
(Travers et al., 2000). The UPR and ER degradation are thereby closely connected. 
Overexpression or accumulation of unfolded proteins due to the absence of a component of the 
ER degradation machinery induces the UPR which, consecutively, upregulates the total level 
of components of the ER degradation machinery (Meusser et al., 2005).  
Another fate for the misfolded protein can be aggregation, which may then be segregated into 
sub-regions of the ER. The size 
of the aggregates varies from 
small oligomers to complexes of 
several million daltons. Because 
aggregates are more stable than 
the intermediate conformation 
from which they are derived, the 
ultimate fate of the unfolded 
proteins is determined by the 
kinetic partitioning between 
proteasomal degradation and 
aggregation (Marquardt and 
Helenius, 1992; Sitia and 
Braakman, 2003). 
Figure 10. Possible fates of newly translocated proteins in the ER. A 
nascent protein is transported across the ER membrane trough the 
protein translocation channel (Red). The unfolded protein can either fold 
or be mis-folded. Folded proteins leave the ER through vesicle transport. 
Mis-folded proteins are tried refolded by chaperones and foldases. 
Terminally mis-folded proteins are either aggregated or degraded. 
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ER-associated degradation  
Misfolded proteins are not degraded in the ER but require retrotranslocation across the ER 
membrane, probably via the Sec61 translocon (Matlack et al., 1998), into the cytoplasm and 
subsequent degradation by the 26S proteasome (Ellgaard and Helenius, 2003; Zapun et al., 
1999; Hirsch et al., 2004; Sommer and Wolf, 1997). The retrotranslocation through the Sec61 
requires unfolding of the misfolded protein. Consistent with this, it has been shown that 
unfolding and reduction of disulphide bonds are a perquisite for dislocation to the proteosome, 
and there is evidence that both BiP and PDI also are involved in this step (Tsai et al., 2001; 
Winkeler et al., 2003) 
Following retrotranslocation from the ER, nearly all misfolded proteins are polyubiquitniated, 
this serves as signal for proteasomal degradation of cytosolic proteins, as well as proteins in 
the secretion pathway (Thrower et al., 2000). The ubiquitin conjugation enzymes (E2) and 
ubiquitin ligases (E3) mediate ubiquitination, where E3 is the key determinant of specificity in 
ubiquitination pathways, as it recognises the target proteins (Hershko and Ciechanover, 
1998). These enzymes are found both in the cytosol as well as bound to the ER. However, the 
enzymatic domains of the ER associated E2 and E3 face the cytosol. Thus accordingly, only 
proteins completely or partially retro-translocated can be ubiquitinated. Therefore, the most 
important signal for degradation must involve lumenal factors, before the ubiquitination, in, 
or prior to the retrotranslocation process. 
Protein Exit from the ER 
After release from the chaperones, the folded and modified polypeptide chains move from the 
ER by vesicle-mediated transport to the Golgi complex. The transport vesicles are coated with 
the cytoplasmic coat protein II (COPII) made up of the subunits Sar1p, Sec23/Sec24p, and 
Sec13/Sec31p (Barlowe et al., 1994; Salama et al., 1993). Little is known about how fully 
folded and assembled proteins are recognized and packaged into these vesicles. Presumably, 
both receptor-mediated export, as well as diffusion into the transport vesicles (bulk-flow) 
combined with ER-protein retention or Golgi-to-ER retrieval, are in play (Belden and Barlowe, 
2001). The specific protein recruitment is thought to occur as a result of direct interactions 
between sorting signals present on cytosolic domains of cargo molecules and specific receptors. 
The Sec24 of the coat machinery is considered to be the receptor for membrane proteins (Miller 
et al., 2003; Mossessova et al., 2003) and the cycling lectin ERGIC-53 has been suggested to 
act as the lumenal sorting receptor for glycoproteins (Appenzeller et al., 1999). However, these 
receptors seem dispensable for the secretion of soluble proteins, like invertase (Springer et al., 
2000), and the identification of an export signal on these proteins remains elusive. But the 
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Erv29 has recently been suggested to function as a transmembrane receptor for the export of 
certain soluble proteins (Otte and Barlowe, 2004; Belden and Barlowe, 2001).  
Evidence for the bulk-flow model is apparent, since cytosolic proteins are secreted when they 
are translocated into the ER lumen via fusion to signal peptides. Indeed, the rate of secretion 
is in some cases comparable to that of natural secretory proteins, but the mechanisms of bulk-
flow, are poorly understood. Retention of some ER residents, through competition or steric 
hindrance, could account for the enrichment of cargo molecules in transport vesicles without a 
requirement for active sorting. The fact that chaperones and other folding proteins are part of 
large complexes could also minimise diffusion into transport vesicles, and since unfolded or 
partially folded proteins bind to the chaperons, they are retained as well (Sitia and Braakman, 
2003). Another model is recycling of ER chaperones and folding helpers that often contain 
signals recognized in the Golgi complex and promote retrieval into the ER by retrograde 
vesicles. Misfolded proteins can thus be recovered from the Golgi complex by virtue of their 
association with a recycling chaperone (Phillipson et al., 2001). The retrieval and retention 
mechanisms are not mutually exclusive, but can very well coexist.  
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 Sz. pombe - a uni-cellular host resembling higher eucaryotes 
Schizosaccharomyces pombe (Sz. pombe) − or fission yeast − is a unicellular eukaryote in the 
class of Ascomycetes yeasts and taxonomically and evolutionary distant from budding yeast 
(Russell and Nurse, 1986). In the 1890’s it was isolated from millet beer from East Africa 
(“pombe” means beer in Swahili). Sz. pombe proliferates by dividing like animal and plant 
cells, while other common yeast as Saccharomyces cerevisiae proliferate by budding. “Schizo” 
means division or fission, and accordingly the name Schizosaccharomyces pombe derives from 
the fact that it originates from beer and its mode of proliferation.  
Sequencing the Sz. pombe genome was completed in 2002, thereby making it the sixth 
eukaryote genome to be completely sequenced (Wood et al., 2002). The genome composed of 
three chromosomes is 13.8 Mb, and the total number of genes is estimated to 4824, about 1000 
less than in S. cerevisiae. Notably, about 50 disease-related genes in humans are also present 
in Sz. pombe. Due to the apparent similarity to higher organisms in terms of the mode of 
proliferation, Sz. pombe has long been used widely as a model for cell division in research in 
molecular genetics and cell biology. In 2001 Paul Nurse received the Nobel Prize in Medicine 
for his research on the cdc2 gene, which is the key regulator of the cell cycle in Sz. pombe.  
Although, Sz. pombe is classified as yeast, it has several properties similar to higher 
eucaryotic organisms, but different from that of other yeast. Apart from the cell cycle control 
these properties include: i) promoter organization − a number of mammalian promoters 
including SV40 and hCMV promoters are active in Sz. pombe. This is not surprising since, the 
transcription mechanism is similar to that of higher animals and the transcription initiation 
site is located 25 to 30 bp downstream of TATA box (Dieci et al., 2000; Jones et al., 1988; Brys 
et al., 1998); ii) gene splicing − introns can be found in 43% of Sz. pombe genes (Kaufer et al., 
1985); iii) organelle morphology (Russell and Nurse, 1986); iv) post-translational modification 
of proteins, like glycosylation (Chappell and Warren, 1989; Tanaka et al., 2005), v) 
chromosome structure and function (Yanagida, 1990), vi), and codon usage (Giga-Hama and 
Kumagai, 1999).  
Heterologous protein expression in Sz. pombe 
Due to similarities to higher eukaryotic cells, together with the features of its facile use as a 
unicellular microbial host, Sz. pombe is widely adopted as a model organism for cell biology 
studies (Giga-Hama and Kumagai, 1999). Also, since eucaryotic proteins expressed in Sz. 
pombe are more likely to be properly folded, recombinant expression in Sz. pombe can reduce 
the protein insolubility problems found in E. coli. 
Wild-type Sz. pombe is prototrophic and therefore capable of growing on minimal media i.e., 
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media that have the minimal number of nutritional components to support growth. 
Auxotrophic strains have been developed to provide the basis for selection of successful 
transformation of complementing plasmids on minimal media. The most commonly used 
selectable markers used in yeasts are requirements for leucine (leu2), uracil (ura3), histidine 
(his3), and tryptophan (trp1) (Siam et al., 2004).  
Classical studies in S. cerevisiae and Sz. pombe genetics have generated a wide array of 
potential cloning vectors (Siam et al., 2004), and, in the process, defined which plasmid and 
host genomic sequences are important in expression technology. Autonomous replication 
sequences (ARS) in the chromosomes of Sz. pombe have been isolated, which can promote 
replication and maintenance of plasmids (Okuno et al., 1997; Dubey et al., 1994; Maundrell et 
al., 1988). The region required for replication is several hundred base pairs long, much longer 
than that of S. cerevisiae. No single copy plasmids have been described for Sz. pombe, because 
the centromere is too large to be placed in a typical bacterial shuttle vector (Siam et al., 2004). 
Because of this, fission yeast has a high loss of plasmid even under selection, so 10-50% of cells 
in a culture have lost the plasmid (Hayles and Nurse, 1992). There have, however, been 
developed integrating vectors to circumvent this problem. 
Effective protein secretion into the media can be achieved in Sz. pombe employing different 
signal peptides, among these are the pGKL killer toxin signal peptide used for expression of 
Mouse α-amylase (Tokunaga et al., 1993), Plus (p) pheromone signal peptide for expressing 
streptokinase (Kumar and Singh, 2004) and interleukin-6 secreted employing its own signal 
peptide (Giga-Hama and Kumagai, 1999). Secretion is beneficial when expressing recombinant 
proteins, since expression of the protein into the culture media makes purification much 
easier. Furthermore, while going through intracellular organelles as ER and the Golgi 
apparatus, secreted proteins undergo correct folding, disulfide bonding, and glycosylation. As 
in eukaryotic cells the Golgi apparatus in Sz. pombe is well organised and morphologically 
distinct (Smith and Svoboda, 1972), while S. cerevisiae has poor Golgi morphology (Chappell 
et al., 1994; Chappell and Warren, 1989), thus affecting the nature of the post-translational 
modifications carried out. However, as in S. cerevisiae, there is a considerable protease 
activity in Sz. pombe both intracellular and extracellular (Kjaerulff and Jensen, 2005; Kumar 
and Singh, 2004; Tokunaga et al., 1993). The proteolytic degradation can be impaired by 
adding peptone to the media (Kjaerulff and Jensen, 2005). The peptides from the peptone may 
function as substrate for the proteases, thereby protecting the protein of interest from 
proteolysis.  
The OD600 at the starting point of the expression influences the yield from secreted 
recombinant protein, probably due in part to the presence of proteases. An optimal starting 
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point is observed at OD600=0.3 for the protein streptokinase. Furthermore, higher expression 
efficiency is seen when the pre-culture is grown in YEA media opposed to minimal media 
containing thiamine. Expression of the recombinant protein causes a decrease in growth rate 
of approximately 50% (Kumar and Singh, 2004). 
The post-translational modifications of proteins carried out in Sz. pombe reflect the elaborate 
secretion apparatus. The oligosaccharide processing is more complex than in S. cerevisiae, 
although different from mammalian cells, and it has been shown that Sz. pombe has a 
membrane localised galactosyltransferase in the Golgi, homologous to the one found in 
mammalian cells (Chappell et al., 1994; Chappell and Warren, 1989). Also N-acetylation, 
isopenylation (Giannakouros et al., 1992), phosphorylation, and myrisylation (Jakubowicz et 
al., 1993; Koegl et al., 1995) are reported to occur in Sz. pombe. 
One of the most commonly used promoters for recombinant expression in Sz. pombe is the 
promoter nmt1 (no message in thiamine)  (Siam et al., 2004). This promoter is regulated by 
the concentration of thiamine in the media − it is active in the absence of thiamine, and 
turned off by the presence of more than 15 µM thiamine. The induction ratio of the promoter is 
about 300-fold. In Sz. pombe the nmt1 promoter is more than 80% stronger than the 
commonly used S. cerevisiae derived adh promoter. A shortcoming of the nmt1 promoter is 
that it is very slowly induced following exclusion of thiamine from the growth medium. The 
promoter requires approximately 16 hours for full induction, probably as an effect of 
exhaustion of thiamine in the cells. Importantly, in rich media containing yeast extract, 
enough thiamine is present to repress the promoter; therefore, expression requires synthetic 
media without thiamine (Siam et al., 2004).  
Lastly − as an important feature for an expression host for therapeutic proteins − Sz. pombe 
meets the basic requirements for safety described in the Recombinant DNA Technology 
Industrialization Guideline (Ministry of Economy, Trade and Industry Notice No. 259 in 
1998). In addition, Microorganisms Safety Information Data of Recombinant DNA Technology 
Industrialization Information System of METI shows that Sz. pombe is found in fruits (apples 
and grapes) and food (grape juice, palm wine, sugar cane and syrup) as reference data for 
long-term use of microorganisms. 
Invertase – as selectable marker in yeast 
Invertase has been used extensively as a selectable genetic marker in yeast and is therefore 
attractive as a reporter for screening and selection. The gene encoding invertase in Sz. pombe, 
Inv1, has been cloned and is the sole gene responsible for invertase activity in this yeast. The 
molecular mass of the protein part of invertase is 60 kDa per subunit and in the glycosylated 
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form the molecular weight is 120 kDa (Moreno et al., 1990). The enzyme (also called beta-D-
fructofuranoside fructohydrolase) is almost exclusively located in the cell wall outside the 
plasma membrane, attached to the cell wall, where it conducts the enzymatic reaction of 
hydrolysing sucrose to glucose and fructose (Figure 11).  
Fructose and glucose, but not sucrose, can be imported into the cell and utilised as carbon 
source in the metabolic pathway. Therefore, the secretion of invertase is essential for cell 
survival when growing in an environment containing only sucrose (Carlson et al., 1983). 
Several assays have been developed to measure the presence of invertase both quantitatively 
and qualitatively (Darsow et al., 2000). 
Because invertase secretion is essential only for growth on sucrose, the cell viability can be 
maintained under growth on other carbon sources. Therefore, the enzyme is a convenient 
marker in genetic selection. It has been widely used to measure the effects of mutations within 
signal sequences (Perlman et al., 1986; Ngsee et al., 1989; Kaiser et al., 1987), to identify 
amino acid sequences mediating localization to yeast vacuoles (Saalbach et al., 1991; Tague et 
al., 1990; Klionsky et al., 1988), and to monitor the amounts of human proteins expressed for 
commercial purposes (Hitzeman et al., 1990). Furthermore, the choise of invertase marker is 
supported by the fact that the invertase protein has been shown to be tolerant to many 
different amino terminal extensions (Jacobs et al., 1997; Kaiser et al., 1987), and invertase as 
reporter protein has been utilised in the signal sequence trap developed by Klein et al. (Klein 
et al., 1996). This S. cerevisiae based system identifies signal sequences by fusing a library N-
terminally to the mature form of invertase; thus, signal sequences can be detected on the basis 
of the ability to grow on sucrose as carbon source. 
 
Figure 11. Sucrose is hydrolysed to fructose and glucose by invertase 
Sucrose, is a disaccharide composed of an alpha-D-glucose molecule and a beta-D-fructose molecule linked by an 
alpha-1,4-glycosidic bond. Invertase is a b-fructofuranosidase that hydrolyses sucrose as well as other b-fructans 
such as raffinose.  
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 Tumor necrosis factor α - a relevant and recognised target  
TNF-α has often been used as model target to test new therapeutic approaches for protein 
down regulation, as it is a significant contributor to the pathology of a number of diseases 
associated with chronic inflammation such as Rheumatoid Arthritis and Crohn’s disease. 
Inhibition of TNF-α activity significantly benefits these patients (Dinarello, 2000; Feldman et 
al., 1998). It has been recognised as target for therapeutic vaccination and has been a target 
for an AutoVac vaccine at Pharmexa (Dalum et al., 1999). The considerable in-house 
knowledge of TNF-α as well as the existence of TNFα specific tools made it an obvious model 
protein for the work presented here. Recombinant TNF-α has been produced in E. coli as 
soluble protein both at Pharmexa and other laboratories (Van, X et al., 1994). The task to 
introduce foreign epitopes in TNF-α has not been trivial. A prerequisite for soluble 
recombinant expression in E. coli is the formation of trimers - monomeric TNF-α is not 
soluble. Also, it has been reported that many single-point mutations results in insoluble 
protein expression (Nielsen et al., 2004).  
Biology of Tumor necrosis factor α 
TNF-α, named after its activity to cause tumor necrosis in vivo when injected into tumor-
bearing mice, is a multifunctional proinflammatory cytokine belonging to the TNF super-
family (Bodmer et al., 2002). Many names have been previously given to the protein 
originating from its biological activity as cachectin, necrosin, macrophage cytotoxic factor, 
macrophage cytotoxin, cytotoxin, haemorrhagic factor, and differentiation-inducing factor. 
These factors have in time been recognised as the same and are now known collectively as 
TNF-α (Old, 1988; Das, 1991). TNF-α exerts an extreme spectrum of biological processes and 
is capable of acting independently and in conjunction with a variety of other factors to affect 
the phenotype and metabolism of cells in every tissue of the body. The actions of the TNF-α 
can therefore be quite complex. TNF-α shows a notable functional duality, being involved in 
both tissue development and destruction (Sugarman et al., 1985). Tissue type, cellular context 
and TNF-α receptor composition, timing, and duration of TNF-α action are important 
parameters influential on the overall effect of TNF-α action. 
TNF-α is mainly produced by macrophage (Ruddle, 1992), but also by a broad variety of 
different tissues and cells. However, it is generally thought that TNF-α is not produced 
constitutively by normal cells, but instead, potently induced by invasive challenges caused by 
neoplastic or infectious disease perpetuating inflammatory responses (Roach et al., 2002). 
A trimeric structure is characteristic for all members of the TNF family, and the ligand-
induced trimerisation of their receptors seems to be the critical event in initiating signalling 
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(Bazan, 1993). Both the membrane-bound and the soluble secreted forms of TNF-α show 
biological activity (Kriegler et al., 1988; Luettig et al., 1989).  
The most profound TNF-α activity is that of proinflammatory mediator, but the molecule has 
optional capacity to induce apoptosis. In concert with other cytokines, TNF-α is considered to 
be a key player in the development of septic shock (Mannel and Echtenacher, 2000). Whereas 
high concentrations of TNF-α induce shock-like symptoms, the prolonged exposure to low 
concentrations of TNF can result in a wasting syndrome, that is, cachexia. This can be found, 
for example, in tumor patients. Also, many other effects are known, including cell 
proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNFα is cytotoxic 
for many cells, especially in combination with γ-interferon.  
The multiple biological effects of TNF-α are mediated by two distinct cell surface TNF-α 
receptors (TNFR1 and TNFR2). TNFR1 and TNFR2 activate different intra-cellular signal-
transduction pathways and modulate expression of a broad number of genes (Brockhaus et al., 
1990). Not only is the ratio of TNFR1 to TNFR2 important to decide which effect TNF-α has 
on a specific cell type, but also the levels of the several different intracellular mediators are 
critical for the physiological effect (Locksley et al., 2001). TNFR1 is constitutively and 
ubiquitous expressed in most tissues, whereas expression of TNFR2 is highly regulated and is 
typically found in cells of the immune system. So, in most cells, TNFR1 appears to be the key 
mediator of TNF-α signalling, whereas in the lymphoid system TNFR2 seems to play a major 
role. TNFR1 binds membrane-integrated as well as soluble TNF-α. However, only membrane 
bound TNF-α, and not soluble TNF-α, can activate this receptor (Grell et al., 1995). 
One TNF-α trimer binds three TNF-α receptor molecules (Vandenabeele et al., 1995) and this 
ligand-dependent trimerisation of the receptors was long considered as the key event for 
signal initiation. However, the receptor activation appears to be more complicated (Chan et 
al., 2000). Ligand binding to the preformed TNFR complex either induces an activating 
conformational change of an already signal competent receptor complex or it allows the 
formation of higher-order receptor complexes, whereby it acquires signal competence. 
Clinical indications of TNF-α up-regulation 
Neutralisation of TNF-α by soluble receptors or monoclonal anti-TNF-α antibodies (Feldman 
et al., 1998; Dalum et al., 1999; Feldmann and Steinman, 2005; Taylor et al., 2004; Elliott et 
al., 1993) point to attractive therapies for TNF-α-mediated disorders. There are several 
clinical indications, where TNF-α plays a central pathogenic role generally characterised by 
chronic inflammation. These indications include, rheumatoid arthritis, Crohns disease, 
psoriasis (Feldman et al., 1998), and cancer cachexia (Natanson et al., 1989; Tracey et al., 
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1988). Given the far-reaching effects of TNF-α on both the innate and adaptive part of the 
immune system, disruption of TNF-α signalling pathways leads to increased susceptibility to a 
variety of pathogens, in particular, those known to survive intracellularly (Marino et al., 
1997). TNF-α or TNFR1-deficient mice show enhanced sensitivity when challenged with 
Mycobacterium tuberculosis, Lysteria monocytogenes, Toxoplasma gondii, or Leishmannia 
major (Flynn et al., 1995; Rothe et al., 1994; Vieira et al., 1996; Deckert-Schluter et al., 1998). 
Furthermore, data from patients who have been treated with an antagonising TNF-α activity, 
show susceptibility to infection and reactivation of latent tuberculosis early after 
commencement of anti-TNF-α therapy (Wolfe et al., 2004; Wagner et al., 2002). However, no 
serious adverse effects have been shown, and anti-TNF-α therapy is considered safe. 
Structure of TNF-α 
The TNF-α molecule is expressed as a non-glycosylated type II transmembrane protein 
arranged in stable homotrimers (Kriegler et al., 1988; Tang et al., 1996). This membrane-
integrated form is processed by posttranslational proteolysis by the metalloprotease TNF-α 
converting enzyme (TACE) releasing a soluble homotrimeric molecule (Black et al., 1997). The 
TNF-α monomers self associates into a soluble non-covalently bound symmetrical trimer of 51 
kDa (Jones et al., 1989). 
The crystal structure of the human 17 kDa soluble TNF-α has been resolved to a 1.8 Å 
resolution (Eck and Sprang, 1989; Cha et al., 1998; Jones et al., 1989) and the murine 
Figure 12. Diagram depicting the β-strands of TNF-α. The TNF monomer is a β-sheet sandwich composed of an inner 
and outer sheet β sheets each made up of 5 β-strands. The inner sheet faces the trimer interface (Eck& Spangs, 
1989). The strands are named starting from the N-terminal 
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structure to a resolution of 1.4Å  (Baeyens et al., 1997). The main chain topology of the TNF-α 
monomer is a β-sandwich formed by two anti-parallel β-sheets, both comprising five β-strands, 
forming a 'jelly roll' -structure (Narhi et al., 1996), typical for the TNF ligand family and some 
viral capsid proteins (Bazan, 1993) (Figure 12). The β-strands A, H, C, and F make up the 
inner sheet of the jelly roll and are involved in trimer contacts. The outer sheet is made up of 
strands B, G, D, and E, which form the outer surface of the trimer. Strand b in this outer 
sheet is interrupted, at its amino terminus (residue 26) with a 20 amino acid chain forming 
strands A’ and B’ A disulfide bridge is found between the loop connecting strands C and D with 
the loop connecting strands E.  
The measure of relative flexibility yielded from the crystallographic data (Jones et al., 1990) 
shows that the β-strands forms a quite rigid scaffold, particularly the inner sheet situated at 
the core of the trimer (Figure 13). This type of structure provides a very stable core 
arrangement from which connecting loops can provide structural variations. The loops linking 
the strands of the outer sheet are more flexible than the ones of the inner. The C-terminus is 
embedded in the base of the inner β-sheet, in close proximity to the N-terminus. The N-
terminus is highly flexible and, as far as residue 10, fairly independent of the rest of the 
molecule, and the first six amino acids can be deleted without loss of activity (Beutler and 
Cerami, 1988). Lysine-11 forms an iron pair with the C-terminal leucine-157, stabilising the 
tertiary and quaternary structure. 
 
Figure 13 Three-dimensional structure of TNF-α. The molecule is presented as timer shown top-view or side-
view. Structure coordinates Protein Data Bank code tnf1A 
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The inner β-sheet is relatively flat, but the surface of the outer is quite curved. The spatial 
distribution of residue side chains is typical of β-sandwich proteins; the interior is closely 
packed, largely with hydrophobic amino acids. The TNF-α trimer is a compact molecule and 
the three subunits tightly interact to form a solid conical shape with loops protruding out from 
the core. The majority of the interactions between the subunits implicate hydrophobic 
residues. The receptor-binding domain is found in the bottom of the bell shape of the trimer 
(Eck and Sprang, 1989), where also the N- and C-terminus as well as lysine-11 are situated.  
 Rational design of TNF-α vaccine candidates 
In order to make rational designed vaccine molecules, suitable sites for T cell epitope 
insertions have to be identified (Nielsen et al., 2004). By examining the crystal structure of 
TNF-α, a flexible loop was identified as being the only region in the molecule which was not to 
proposed to have intra- or inter-molecular interactions, and accordingly it was chosen for 
epitope insertion. The insertion causes extension of the loop potentially destabilising the TNF-
α molecule; therefore an extra cysteine bridge was introduced in some vaccine candidate 
molecules. Another approach was to connect the three TNF-α monomers that then could form 
a trimer-like molecule. The “monomers” were interconnected by two Th-cell epitopes that 
consequently need not to be included in the actual TNF-α structure, and in this way 
accomplished minimal disturbens to the structure. Both approaches resulted in a soluble 
protein expression in E. coli of some of the variants. Subsequent testing revealed that these 
TNF-α variants were as stable as wt-TNF-α and their biological activity comparable to wt-
TNF-α.  
In the TNF-α vaccine project at Pharmexa 12 different insertion sites have been predicted by 
rational design (Nielsen et al. 2004, unpublished in-house data from Pharmexa). Further, due 
to partial substitutions and other modifications 30 different TNF-α AutoVac proteins were 
suggested, designed and tested for folding competence. These rational predictions were, among 
other things, based on the crystal structure of human TNF-α, superimposing human and 
murine crystal structuresm, as well as by evaluating sequence alignments of TNF-α from 
species in which orthologue homologues have been identified and from other members of the 
TNF-α superfamily (Nielsen et al., 2004). The AutoVac candidates were made by site-directed 
mutagenesis and tested for expression capability in E. coli, before a candidate for animal 
testing was selected. Of the 12 different insertion sites 4 were able to accommodate the 
epitope insertion and only two showed a satisfactory level of expression. Hence, finding 
AutoVac variants requires considerably time and resources. Therefore, a complementary 
approach will be much appreciated.  
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RESULTS 
The result section is divided into 5 main parts: 1) Generation of the TNF-α library, 2) analysis 
of the library, 3) generation of the Sz. pombe screening host, 4) screening/selection of folding 
competent variants, and 5) analysis of selected variants.  
 
Generation of the TNF-α library 
Rationale of the library plasmid construction. 
The first step in project was the generation of a library TNF-α AutoVac variants with PADRE 
distributed randomly along the whole TNFα sequence. A library generation plasmid was made 
from the pUC19 plasmid (Yanisch-Perron et al., 1985) (Figure 14), which, besides being small 
in size, has the notable feature of being free of Not1 restriction sites used in subsequent steps. 
The promoter sequence was removed from the plasmid to delete any expression from the 
plasmid that could introduce bias in the library. Further, the restriction sites for Nco1 and 
Sac1 were introduced at the 5’-end and 3’-end of TNF-α, respectively. These sites facilitate 
that the library readily can be moved from this plasmid into a plasmid suitable for screening 
in Sz. pombe. The resulting plasmid is only 2910 base pairs long, including the TNF-α 
sequence. The small size ensures that the transposon integrates with high frequency in the 
TNF-α cDNA sequence. 
hTNF-wt(pUC19)
2910 bp
hTNF
APr
P(BLA)
P(LAC)
ORI
HindIII (2)
NcoI (2430)
NdeI (2425)
SacI (2910)
 
Figure 14. Schematic representation of the library generation plasmid 
TNFα cloned into the pUC19 plasmid. Flanking the TNF-α coding cDNA is Nco1 and Sac1 restriction sites, 
facilitating the transfer of the library to the screening plasmid. The plasmid contains no Not1 sites, which is 
flanking the transposon and will be used in the subsequent steps. The promoter sequence of the plasmid has been 
removed to avoid any expression of the insert. 
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Overview of the library generation steps 
In order to generate a PADRE insertion library of TNF-α, a Not1 restriction site is randomly 
inserted in the TNF-α cDNA sequence by transposition. After the insertion the transposon is 
removed by the Not1 restriction enzyme and replaced by the PADRE epitope. At the same 
time all wt-TNF-α encoding cDNA must be eliminated from the pool of variants to avoid 
background of wild-type protein later in the screen. Thus, a 5-step process was applied to the 
library plasmid (Figure 15); i) in vitro transposition, ii) isolation of mutagenised TNF-α cDNA 
iii) reintroducing mutagenised TNF-α cDNA into vector, iv) interchanging transposon with the 
PADRE epitope, v) transferring the library to the screening vector.  
 
In vitro transposition  
The transposon was inserted into the plasmid using the MuA based transposon MGS Kit from 
Finnzymes (Figure 16). This kit contains a MuA transposases and a linearly DNA transposon 
(Entranceposon). The transposon has been genetically engineered by introducing Not1 sites 
near each rim of the transposon, whereby the bulk of the transposon can be removed. After 
transposon removal, the residual sequence comprises 15 base pairs made up by 10 bases 
holding the Not1 restriction site and a 5 base pair duplication of the target site. In order to 
 
Figure 15. Construction of the TNF-α insertional Library.  
1) The Entranceposon and transposase are reacting with the acceptor plasmid integrating transposon 
randomly herein.The plasmids are transformed into E. coli and amplified on LB solid media containing both 
ampicillin and kanamycin, ensuring selection only of plasmids with integrated transposon. 2) The transposon 
can be integrated both in the vector as well as in the TNF gene. So, to remove plasmids with vector integrated 
transposons, the TNF-α + Entranceposons insert is reintroduced into the original library vector by use of the 
restriction enzymes NcoI and SacI. 3) Transformants are again selected on LB solid media containing 
ampicillin and kanamycin. This is important to eliminate any wt TNF from the pool of variants that later 
could show up as false positives in the screen. 4) Now the Entranceposon is ready to be replaced with the 
PADRE epitope. To do so the Entranceposon is removed by use of the restriction enzyme Not1. The open 
plasmid is ligated together with a DNA fragment encoding the epitope, having convertible ends. The resulting 
plasmid is amplified on LB solid media containing ampicillin. The TNF-α library is ready for introduction into 
the screening vector. 
1 2 3 4 
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ensure as many hits as possible, the reaction was performed on a PCR thermoscycler where 
the temperature can be precisely regulated and remains constant to achieve optimal 
conditions for transposition. Furthermore, to attain as many insertions as possible, the 
reaction time was extended from 1 (suggested in the suppliers manual) to 3 hours (in my 
reserch). 
After the transposon reaction the reaction was divided into 20 aliquots, and 7 of these were 
transformed into E. coli cells plated onto 7 plates of solid LB-media containing kanamycin 
(antibiotic marker for the Entranceposon) and carbencillin (antibiotic marker for the plasmid). 
The double selection ensures that only plasmids containing the transposon are able to amplify. 
In all, 35,000 colonies appeared on the seven plates representing equal numbers plasmid with 
independent transposon insertions. The 7 reactions were kept independently as parallel 
reactions throughout the library generation. 
 Isolating the mutagenesised TNF-α cDNA  
Plasmids where the transposon has integrated in the vector, and hence left the TNF-α 
sequence intact, are not acceptable in the pool of plasmids, since they would lead to a 
background during the screen and must therefore be removed. Therefore, the plasmids are 
digested with Nco1 and Sac1 flanking the TNF-α cDNA, to select inserts holding the 
transposon and the fragment comprising TNF-α plus the transposon (Figure 17).  
On the basis of the intensities of the bands appearing on the agarose gel, the transposon 
integration was estimated to have occurred in the cDNA of TNF-α in 50% of the plasmid 
molecules. Assuming that the modified Mu transposon behaviour is random, the probability of 
insertion in the TNF-α coding sequence during transposition should be the ratio of the coding 
5’NNN 12345 TGCGGCCGCA 12345 NNN3’
3’NNN 12345 ACGCCGGCGT 12345 NNN5’
5bp duplication15bp insertionRandom target 
site
A
B
 
 
Figure 1.3 Reaction steps in the transposon MGS Kit from Finnzymes 
A) The MGS system introduces 15 bp insertions at random positions in target plasmid DNA by use of 
Entranceposons and the MuA Transposase. The Entranceposon holds the kanamycin resistance gene. 
B) A 15 bp insertion is left after transposon removal, including the Not1 recognition sequence and a 5 bp 
duplication 
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sequence to the size of the total plasmid (approximately 20%). However, transpositions that 
disrupt critical elements of the plasmid (the plasmid origin or the Ampr gene, constituting 
about half of the vector) will not be recovered after transformation, thereby increasing the 
relative number of hits in the TNF-
α cDNA compared to the overall 
number of hits in the plasmid. 
Consequently, as half of the 
transposon integrations are in the 
TNF-α cDNA, the other half is in 
the vector now removed, the 
number of individual transposon 
insertions in the TNF- cDNA in the 
library was estimated to 17,500. 
 Reintroducing the cDNA into the library vector 
After isolation the fragment with the TNF-α and transposon was ligated into a pristine library 
vector. In order to achieve as many transformants as possible and thereby maintain a high 
diversity of the library despite of the many steps in the library protocol, several measures 
were taken. Firstly, E. coli preparation of high transformation efficiency (1x1010 transformants 
/µg) was used. Secondly, the ligase was heat inactivated before transformation, a step that has 
shown to increase the transformation efficiency 10-260 times (Ymer, 1991; Michelsen, 1995). 
And thirdly, the ligation mix was desalted by dialysis against milliQ water through a 
Millipore 0.05 um VMTP membrane in order remove residual salt from the reaction (Jacobs et 
al., 1990).  
The transformed E. coli cells were again subjected to double antibiotic resistance selection. 
The E. coli transformations were very efficient. The colonies were confluently covering the 
plates so their number could not be estimated accurately. Ideally the transformants should 
have been plated out on additional plates. However, based on practical experience, colony 
numbers up to around 6000 per plate can be estimated by counting. Therefore, I estimate that 
the confluent layer represents, at least 3 fold more, which is 126,000 in this experiment 
comprising 7 plates. Thus, as intended, the high number of transformants ensured that the 
size of the library was not compromised. Hence, the number of single mutagenic events in the 
TNF-α library was kept at 17,500. 
 
 
M    1    2    3    4    5    6    7  V 
500 
1031 
1500 
2000 
3000 
2400 
600 
3600 
1700 
500 
 
Figure 17. Inserts containing transposon are selected. The plasmids 
are digested with Nco1 and Sac1.  
Fragments from the 7 independent transposon reactions are run at an 
argarose gel. Fragment of 3600bp (transposon + vector), 2400bp 
(vector), 1700bp (TNF-α cDNA + transposon) and 500bp (TNF-α 
cDNA) are seen. V is the wt-TNF-α pUC19 vector prior transposition. 
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 Interchanging the transposon with the PADRE epitope 
The next step was to remove the transposon and replace it with the PADRE epitope. The 
library plasmids were digested with Not1, as two Not1 sites flanks the transposon, and 
subsequently treated with calf intestine phosphatase to remove the phosphate units at the 
DNA fragments (Figure 18). Digesting a PADRE containing plasmid (PADRE pVax) with Not1 
retrieved a PADRE insertion fragment. In this way the PADRE sequence is compatible with 
the Not1 restriction sites left after transposon. The reason for using a plasmid-derived PADRE 
fragment is that it now has phosphate moieties on the 5’ ends, and therefore can be ligated 
together with the un-phosphorylated vector fragment. This is necessary in order to avoid self-
ligation of the plasmid. If the plasmid closes on itself, it generates TNF-α variants holding the 
15 base pairs insert deriving from the transposon event and not the epitope insertion. 
The resulting plasmids were amplified 
in E. coli cells on carbencillin selection. 
Again the transformation efficiency 
was very high, leading to confluent 
growt, and prohibiting the exact 
number of transformants to be known. 
It was presumed, however, that the 
number of variants was above 126,000 
and therefore that the size of the 
library was not compromised.  
 Transferring the library to the screening vector 
The TNF-α variant library was now ready, and introduced into the vector used for screening, 
described in detail below. In order to do so, the plasmid was digested with Sac1 and Nco1 and 
M    1    2    3    4  5   6     7  
1031
1500
2000
3000
2900
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2500
Figure 18. Removal of the Entranceposon from the TNF-α 
cDNA fragment.  
After Digestion with Not1, fragments were run on an agarose 
gel. 2 bands appeared at 2900 base pairs (vector + TNF-α) and 
1200 base pairs (transposon). 
 
M        1    2    3   4    5    6    7 
500 
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2000 
3000 2400 
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525 
Figure 19. Concatenation of TNF-α insert fragment. In order to move the TNF-α variants to the screening 
vector, the plasmid is digested with Sac1 and Nco1 and 2 bands are expected on the agarose gel at 
525 base pairs (TNF-α + insert) and 2400 base pairs (pUC19 library vector).  
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2 bands are expected on the agarose gel at 525 base pairs (TNF-α + PADRE) and 2400 base 
pairs (vector). Surprisingly, a ladder of inset fragments was observed starting by 545 base 
pairs as the smallest fragment (Figure 19). This was due to an extensive concatenation of the 
epitope DNA fragment during ligation, effected by the phosphorylated insert fragment.  
The solution was to extract the lower DNA fragment from the gel and use it as insert in the 
screening vector. The result from this procedure showed that the approach was successful, 
since no repetition of the epitope was later found in any of the variant sequences. The 545 
base pair fragment was cloned into the screening vector and about 84,000 colonies appeared 
after carbencillin selection. This number of transformants was estimated as sufficient to 
maintain the estimate of 17,500 single transposon hits.  
 
Analysis of the Library 
The TNF-α sequence comprises 474 base pairs between which the insert can be situated and 
the insert can be found in 2 different directions, giving 948 possible different variants of TNF-
α in the library. The library represented 17,500 single transposon hits, so each possible 
sequence would in theory be represented approximately 20 times if the library were 
completely random. This means that the library was likely to be exhaustive. 
The library was now ready for selection, but prior to this, the quality of the library was 
analysed. This was done by randomly picking and sequencing the insert of 44 clones (18 from 
the pUC19 library and 26 from the screening Sz. pombe vector library) (Figure 20). Each clone 
contained one single insert. Insertion points are evenly distributed along the 474 base pair 
long TNF-α sequence, and all, except 2, were unique.  
 
 
The distribution of the insertion sites was tested at the last two steps of the construction of 
the library (see figure 15), to ensure that any biases introduced both during transposition 
event, but also importantly, in the following sub-cloning steps, are displayed in the analysis. 
The library was inserted into the pUC19 library vector, and secondly, in the S. pombe 
ATGGTCAGATCATCTTCTCG AACCCCGAGTGACAAGCCTG TAGCCCATGTTGTAGCAAAC CCTCAAGCTGAGGGGCAGCT 
CCAGTGGCTGAACCGCCGGG CCAATGCCCTCCTGGCCAAT GGCGTGGAGCTGAGAGATAA CCAGCTGGTGGTGCCATCAG 
AGGGCCTGTACCTCATCTAC TCCCAGGTCCTCTTCAAGGG CCAAGGCTGCCCCTCCACCC ATGTGCTCCTCACCCACACC 
ATCAGCCGCATCGCCGTCTC CTACCAGACCAAGGTCAACC TCCTCTCTGCCATCAAGAGC CCCTGCCAGAGGGAGACCCC 
AGAGGGGGCTGAGGCCAAGC CCTGGTATGAGCCCATCTAT CTGGGAGGGGTCTTCCAGCT GGAGAAGGGTGACCGACTCA 
GCGCTGAGATCAATCGGCCC GACTATCTCGACTTTGCCGA GTCTGGGCAGGTCTACTTTG GGATCATTGCCCTCGGAGCT 
            SacI 
Figure 20. Sequence analysis of 44 randomly picked clones. 
44 E. coli colonies containing the screening plasmid were picked and the insert was sequenced in order to establish 
the insertion point of the insert. The insertion site is displayed by highlighting the last base before the insertion in 
red, insertions form the screening Sz. pombe vector are underlined. 
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screening vector. The results from sequencing of 18 randomly picked clones from the pUC19 
vector and 26 clones from the S. pombe vector are presented in figure 20 in red/bold and 
red/bold/underlined, respectively. In both cases, the results show that the insertion sites are 
distributed randomly. Furthermore, this shows that no biases occurred during the 
transposition events, nor during the following sub-cloning step. 
The DNA fragment can translate into 6 different amino acid sequences. This derives from the 
fact that the insert can be found in 2 orientations (direct and reverse) and 3 reading frames 
(RF1, RF2, RF3) (Figure 21). Therefore, the sequences were analysed for the distribution of 
the different amino acid sequences, so as to reveal if any biases were present in the library.  
 
 
The distribution of insertion sites and sequences is shown in Table 1. Theoretically, if the 
transposition were truly random, the inserts should be found in 33% in each of the 3 reading 
frames. The data show that the distribution varies between 30-36%, indicating that the 
transposition has indeed been random, and analysing the two libraries individually, the same 
conclusion can be made. Of the 44 clones analysed, 18 have insertion sequences in the direct 
orientation (41 %) and 27 (59%) in reverse orientation, correlating well to the expected 50%. 
If both the orientation and the reading frame be taken into account, the expected distribution 
would be 16% for each of the 6 possibilities. A distribution between 9% and 22% was found, 
corresponding well with the value of 16%. The sequences translate into 6 different amino acid 
sequences, 2 of which contain stop codons. Of the 4 viable sequences, the distribution was 
 
 
Figure 21. Possible amino acid sequences of the inserted fragment. 
The red bases represent the target DNA (these bases were chosen arbitrarily here but they differ 
depending on the target sequence), the black bases the Not1 restriction sites, and the blue are 
representing the insert. The insert can be found in 2 orientations (direct and reverse) and 3 reading 
frames (RF1, RF2, RF3) translating into 6 different insert sequences, 2 of which contains stop codons. 
123 45T  NotI PADRE                     NotI A 123 45
AGC ACT GCG GCC GCT AAG TTC GTT GCA GCT TGG ACC CTT AAG GCG GCC GCA AGC AC
ST AAAKFVAAWTLKAAA ST
XA RPLSSLQLGPLRRPQ QA
XH CGRLKGPSCNELSGR KH
ST AAALRVQAATNLAAA ST
XA LRPP*GSKLQRT*RP QA
XH CGR*VRCSLDP*GGR KH
Reading 
frame
1.
2.
3.
Direct Reverse
Translation
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between 14% and 37%, correlating with the expected distribution of 25%. The PADRE 
sequence was found in 6 of the 44 clones, representing 13% of the cDNA library and 22% of the 
translated library. So, no apparent biases were present in the analysed subset of clones. 
In conclusion, the library exceeds the number of the possible events 20 times and the 
insertions appear random, both in terms of insertion site and of fragment orientation. Thus, 
the library is presumably exhaustive, so all possible sequences can be subjected to the 
subsequent screen of folding competence.  
 
Reading frame of insertion point 
 (33%) 
Frequency of 
different insert 
sequences pUC19 
library  
Sz. pombe 
library 
Total 
Resulting insert 
DNA sequence 
(16%) 
Resulting amino acid 
insert sequence  
Frequency prior 
screening  
(25%) 
RF1-d (PADRE)  6 (13 %) AAAKFVAAWTLKAAA  6 (22%) 
RF1-r 
6 (33 %) 10 (38 %) 16 (36 %) 
10 (22%) AAALRVQAATNLAAA 10 (37%) 
RF2-d 4 (9%) RPLSSLQLGPLRRPQ 4 (14%) 
RF2-r 
5 (28 %) 8 (31 %) 13 (30 %) 
9 (20%) LRPP*GSKLQRT*RP  - 
RF3-d 8 (20%) CGR*VRCSLDP*GGR  - 
RF3-r 
7 (38 %) 8 (31 %) 15 (34 %) 
7 (16%) CGRLKGPSCNELSGRT 7 (25%) 
Total 18 26 44 44   27 
 
Table 1. Frequency of each possible insert sequence found in 44 randomly picked clones.  
The insert can be found in 3 reading frames (RF1, RF2, RF3) and 2 orientations direct or reverse (d, r) translating into 6 different insert 
amino acid sequences, 2 of which contains stop codons. The direct orientation was found 18 times (41 %), whereas the reverse 
orientation was found 26 times (59%). The expected distribution is specified in the parentheses in the top row. 
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 Generation of the screening host and screening plasmid 
The Sz. pombe screening host 
In order to use invertase as selectable marker to screen the TNF-α insertion library, an 
invertase-knockout strain of Sz. pombe was constructed. The invertase knockout was genera-
ted from the Sz. pombe strain Eg660 (mat1-P Dmat2,3::LEU2-leu1 ura4-D18). A one-step gene 
replacement technique (Rothstein, 1983) was used to disrupt the endogenous invertase gene of 
the cell whereby the entire open reading frame was replaced with the ura4 gene. The resulting 
strain (PY-17) showed no invertase activity and was unable to grow on sucrose media.  
 Rational of the screening vector constructions 
The screening vector was generated using the pREP3X1 (Moreno et al., 2000) vector as back-
ground, because this is a shuttle vector (Figure 22). The invertase gene was fused to the Cpy 
signal sequence (Tabuchi et al., 1997; Kjaerulff and Jensen, 2005), to allow secretion of the 
library-invertase hybrid protein. The Cpy-signal sequence has previously been shown able to 
accommodate secretion of invertase, TNF-α, and GFP in Sz. pombe (Kjaerulff and Jensen, 
2005). Between the Cpy signal sequence and the invertase gene, the Nco1 and Sac1 restriction 
sites were situated flanking a STOP codon. The restriction sites allow introduction of the 
library, and the STOP codon prevents background from self-ligated vector to contaminate the 
screen by preventing expression of the invertase gene. A similar strategy to eliminate back-
ground by introducing a stop-codon has previously been described (Olesen & Kielland, 1993).  
 
pCpy-inv1-lib 
10624 bp 
LEU2 
Cpy signal 
sequence 
inv1 
STOP 
nmtp 
ars1
nmtT 
Nco1 
Sac1 
Figure 22 Schematic representation of the Sz. pombe screening vector.  
The Sz. pombe screening vector plasmid consists off the following elements: 1) The Nmt1 promoter (nmtp) and 
terminator (nmtT) for expression in Sz. pombe, 2) the signal sequence from the Cpy gene for supporting 
secretion, 3) the mature invertase gene (minus the signal peptide) (Inv1) as folding marker, 4) NcoI and SacI 
restriction sites, in which the TNF-α variants can be interchanged with the STOP codon and be fused in frame to 
the invertase gene, 5) the leucine gene as selectable plasmid marker for transformants in Sz. pombe, 6) a origin 
for replication in E. coli (ori), 6) and the ampicillin gene (Amp) as selectable marker for transformants in E. coli. 
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 Prediction of Signal peptide cleavage 
The SignalP 3.0 prediction server at Centre for Biological Sequence Analysis at DTU was used 
to evaluate the N-terminus of the Cpy-TNF-α fusion (Bendtsen et al., 2004). This server 
predicts the signal sequence of classically secreted proteins and the cleavage hereof through 
the analysis of the N-termini protein sequence. This predictor uses both Neural Networks and 
Hidden Markov Model algorithms, and is among the most precise methods for protein signal 
sequence prediction which reach accuracy above 80% (Klee and Ellis, 2005). The N-terminus of 
the Cpy-TNF-α fusion protein was submitted to the SignalP prediction server (Figure 23).  
The first output is from the neural network (Figure 23A). This algorithm gives 3 outputs in a 
graphical form; The C-score assigns the ``cleavage site'', which is significantly high only at the 
cleavage site. The S-score is the predicted signal sequence. Y-max is a derivative of the C-score 
combined with the S-score ensuing in a better cleavage site prediction than the unprocessed C-
score, since multiple high-peaking C-scores can be found in one sequence only having one 
factual cleavage site. The cleavage site is designated by the Y-score at the point where the 
slope of the S-score is steep and a significant C-score is found. The prediction from the neural 
network of the Signal 3.0 server gives a most likely cleavage site between residue 18 and 19. 
These residues constitute the border between the Cpy-signal sequence and the N-terminal of 
the TNF-α molecule, indicating that the fusion has not destroyed the features of termination 
sequences and that cleavage should occur as expected. There is, moreover, also a rather high 
Y-value between the residues 23 ands 24.  
The Hidden Markov Model is a statistical model describing the probability of distribution 
between different states, which can be used for pattern recognition applications. The signal 
peptide model contains sub-models describing each of the 3 distinct sequential regions of a 
signal sequence: the N-terminal region, the hydrophobic-region, and the C-terminal-region. 
Furthermore, a likely cleavage site is assigned a probability score. This prediction algorithm 
describe the most likely cleavage site is between residue 23 and 24, but also here a cleavage 
site between 18 and 19 can be predicted. Thus, both the site between residue 18 and 19 and 
the one between 23 and 24 are possible cleavage sites according to the Signal 3.0 server. This 
gives a possibility that the signal sequence be elongated by 5 amino acids, when fusing Cpy 
and TNF-α giving a shorter hybrid protein. Alternatively, a subset of the protein is cleaved at 
one of the positions and another subset at the other.  
The difference between the outputs of the two models is due to the fact, that two different 
algorithms are employed using different input parameters. The prediction is also more tricky, 
since it is a fusion protein that is been analysed. This means that information from both the 
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Cpy signal sequence and the TNF-α combined in the output scores. What cleavage site that is 
used in vivo can be determined empirically by N-terminal peptide sequencing. But 
importantly, there is a strong prediction of a signal sequence and a cleavage site to direct the 
protein to the secretory pathway. This is confirmed by the experimental data showing that the 
Cpy-TNF-α protein is expressed and secreted (Kjaerulff and Jensen, 2005).  
 
 
# Most likely cleavage site between pos. 18 and 19: VSA-MV 
 
Prediction: Signal peptide 
Signal peptide probability: 0.986 
Signal anchor probability: 0.012 
Max cleavage site probability: 0.499 between pos. 22 and 23 
 
Figure 23 Output data from the SignalP 3.0 signal sequence prediction server 
A. The N-terminal of the CPY-TNF-α fusion protein was submitted for signal sequence analysis.  
The output from the neural network of SignalP contains 3 different scores, in a graphical form: the C (cleavage sites), S 
(signal peptide), and Y (combined) score. The scores are reported for each single amino acid position in the submitted 
sequence. 
B. The Hidden Markov Model calculates the probability of whether the submitted sequence contains a signal peptide or 
not. The signal peptide model contains sub-models that describe each of the 3 distinct sequential regions of a signal 
sequence: the N-terminal region, the hydrophobic-region, and the C-terminal-region. A likely cleavage site is assigned a 
probability score. 
B 
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Library screening  
In order to obtain selected folding competent proteins 3 individual screens were done in the 
Py-17 Sz. pombe strain, using the library described above inserted. In the 2 first screens 
different obstacles in the set-up caused abortion of the ongoing screen. The experiences 
obtained were implemented to the following selection round.  
 First round of selection  
Newly transformed Sz. pombe cells are in general known not to survive on sucrose media. 
Therefore, transformed cells were plated out on glucose plates and two different methods for 
screening for invertase activity known from the literature were tested. One is replica-plating 
from glucose to sucrose (or sucrose containing antimycin, an inhibitor of the respiratory-chain 
(Jacobs et al., 1999), to enhance the selection pressure), and the other is an invertase overlay 
assay using red/white colour screening (Paravicini et al., 1992; Johnson et al., 1987). However, 
much background was seen in these approaches, so the positive colonies, having a plasmid 
encoding a foldable sequence, could not be distinguished from negative colonies encoding non-
foldable sequences.  
In the growth assay at least 1/3 of the colonies should not have grown solely on the basis of 
containing stop codons in the insert sequence, and hence the invertase moiety will not be 
expressed. Therefore, it is obvious that a degree of background growth is present. This 
Stop-Inv
TNF-Inv
TNF-Inv Stop-InvStop-Inv
Emm fructose Emm Sucrose Emm Sucrose
Emm fructose 
+ invertase overlay assay
 Figure 24. The cross-feeding of the growth assay and the reaction in the invertase assay are shown. 
Growth assay plate 1-3: TNF-inv: The PY-17 strain transformed with Cpy-TNF-α-inv plasmid possesses invertase activity. 
Stop-inv: The PY-17 strain transformed with Cpy-STOP-invertase encoding plasmid does not possess invertase activity. On 
the first plate is Emm-fructose media giving no selection, both invertase positive and invertase negative strains are expected 
to grow. The second plate is Emm-sucrose selection media. Therefore, only positive cells should sustain growth. But as seen, 
the invertase negative strain also grew. The closer to the positive cells the more profound the growth. If however, no 
invertase positive cells have been streaked onto the plate, no growth is seen in the in the invertase negative cells. 
Invertase assay plate 4: PY-17 cells transformed with the library containing screening plasmid and subjected to invertase 
overlay assay. As seen, about 2/3 of the colonies turn red. There is some differentiation between how fast the colour develops 
in the individual clones, but the development of colour is completed only in seconds in all cases. 
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background can derive from cross-feeding of glucose and fructose diffusing from positive cells, 
making all colonies invertase positive, as well as negative, multiply on the selective sucrose 
plates. To test the hypothesis of cross feeding, the growth among negative cells growing in 
proximity to positive cells was displayed (Figure 24, plate 1-3), using standard plasmids. From 
this test it was apparent that positive cells did sustain growth of negative cells. 
In the invertase assay 2/3 the colonies developed colour corresponding to the amount of 
colonies without stop codon in the insertion sequence (Figure 24, plate 4). Thus, the sensitivity 
of the invertase assay seems too high for the assay to be useful in this context. 
 Second round of selection 
 To circumvent the problems from the previous screen, a new approach using growth on 
limiting glucose was developed. The next round of selection was done by growing 
transformants on solid EMM sucrose media without glucose or with a limiting concentration of 
glucose. The rationale behind the addition of glucose to the sucrose solid media is that the 
limited amount of glucose allows newly transformed colonies to survive on the sucrose media. 
The glucose in the media is soon exhausted, and after this point, only clones containing a 
folded protein-variant, and therefore invertase activity, are capable of continued growth. The 
concentrations tested were 2% sucrose containing 0%, 0.1%, and 0.01% glucose (Figure 25). On 
0.1% of glucose all colonies grew just as well as the ones on glucose plates. But on the 0.01% 
glucose 20 out of 600 colonies grew (3 %). Surprisingly, 2 colonies appeared on the sucrose 
plates.  
Colony PCR was preformed on the positive clones in order to determine the sequence of the 
TNF-α variant present in the colony. However, when attempting to sequence the insert most 
clones yielded no readable sequence, even though getting a DNA fragment of the right size 
from the colony PCR was possible. To investigate this, the DNA fragments from the separate 
selected colonies were cloned into the TOPO vector and transformed into E. coli cells. For each 
transformation a single E. coli colony represented a different plasmid in the yeast cell. From 
each set of the transformation 4 E. coli clones were picked and sequenced. The number of 
different variants per yeast colony varied from 4 out of 4 colonies to a single variant out of 4. 
The multiple plasmids in each cell/colony are likely to derive from the transformation where a 
transformation competent cell can uptake several plasmids. And since the plasmid used is of 
the multi-copy type, it is possible that plasmids encoding variants not able to sustain 
invertase activity are co-transformed and segregate along with those who are.  
Plasmids are easily lost from the Sz. pombe cells, even under selection pressure, and it is 
estimated that up to 50% of the cells in a culture in liquid media are not holding any plasmids 
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(Hayles and Nurse, 1992). Therefore, the answer for reducing the multiple plasmids to one 
was to re-streak the selected colonies twice on sucrose media. Hereafter, only one variant was 
found in each colony displayed by sequencing.  
After re-streaking and performing liquid invertase assay, 4 of the 22 of the colonies turned out 
to be false positives. Therefore, this selection round was aborted, but the use of limiting 
glucose in sucrose media was further investigated, and a double re-streaking was 
implemented in a new round of selection.  
 
 
 
 
 
 
 
 
 
 
 
 
 Optimisation of the glucose concentrations using control proteins 
First, more glucose concentrations in the sucrose plates were tried out (0.01%, 0.02%, or 
0.03%). The test was done using TNF-α protein fused to invertase, but also the RANKL fused 
to invertase was included in the test (Figure 26). RANKL is used in an AutoVac project at 
Pharmexa, belongs to the TNF-α superfamily, and is demonstrated folded/expressed in E. coli, 
and was used inorder to investigate whether different proteins display different growth 
patterns on selective media.  
The Sz. pombe strains containing the TNF-α or RANKL encoding plasmids grew on the 
selected concentrations, also on sucrose media. No differences were noted between the 
 
 
Cpy-TNF-lib  
 
 
Cpy-TNF-inv 
 
  
 
Cpy-STOP-inv  
2% Sucrose 2% Sucrose 
0.01% Glucose 
2% Sucrose 
0.1% Glucose 
2% Glucose  
 
 
Figure 25. Optimisation of the glucose concentration in the screening plates.  
The Py-17 Sz. pombe strain transformed with the screening plasmids either containing a STOP codon, TNF-α, or 
library fused to the invertase gene was plated out on Solid Emm-media with different concentrations of glucose. 
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proteins. Notably, the cells with empty vector only grew on glucose media and none on the 
selective media. At the glucose concentrations 0.01%, 0.02%, and pure sucrose, a reduced 
number of colonies was seen and at the concentration 0.03% as many colonies appeared as on 
glucose plates. The fact that all colonies grew at the concentration of 0.03% does not mean 
that this concentration is too high for selection, as all the transformed cells contain plasmids 
giving a positive phenotype. More important is that there was no growth at this concentration 
on the plates with an empty vector. In all, the results indicate that the right range of glucose 
concentrations for screening had been found. 
It is apperent that an there is an uneven distribution of colonies on glucose concentrations at 
0.01%, and 0.02% and sucrose. It is not quite clear what causes this, but a hypothesis is that 
some colonies have a higher invertase activity than others (maybe because of a higher plasmid 
copy number in these colonies) and, therefore, grow relatively faster than the majority of the 
colonies. These cells then drive the neighbour colonies to grow faster due to cross-feeding with 
glucose. In this context it should be noted that all the clones on these plates contain identical 
plasmids, all with folding competence and hence putative invertase activity. Therefore, this 
tendency may not be a problem when screening a library. Alternatively, subtle differences in 
the environment on the plates, e.g. temperatures or moistness result in the differences in 
growth rate. 
Cpy-RANKL-
inv
Cpy-TNF-inv
Cpy-STOP-
inv
2% Sucrose2% Sucrose
0.03% Glucose
2% Sucrose
0.02% Glucose
2% Sucrose
0.01% Glucose2% Glucose
 
 
 
h Figure 26. Optimisation of the glucose concentration in the screening plates.  
The Py-17 Sz. pombe strain transformed with the screening plasmids either containing a STOP codon, TNF-α or RANKL fused to 
the invertase gene was plated out on Solid Emm-media with different concentrations of glucose 
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Third round of selection 
The experiences of the 2 preceding screens and the glucose optimisation were applied to the 
last and successful screen. Consequently, Sz. pombe cells transformed with the library were 
spread out on 2% sucrose plates with the addition of 0%, 0.01%, 0.02%, or 0.03% glucose 
(Table 2). 3 plates of each glucose concentration were used. Furthermore, one plate of 2% 
glucose was used in order to estimate the number of transformed cells.  
4000 colonies appeared on the glucose plate after 4 days. The selection plates were examined 
daily. No colonies appeared on the sucrose plates. In total 18 and 7 colonies appeared, at the 
concentrations 0.01% and 0.02% glucose, respectively and were picked at day 7 and 8. Growing 
colonies were picked from the selection plates as they appeared, in order to reduce growth of 
satellite colonies due to cross feeding. At the concentration of 0.03 % glucose 1068 colonies 
(10%) grew at day 7, and it was suspected that this concentration of sucrose was not selective 
enough. Therefore, these colonies were replica plated onto pure sucrose media and the fastest 
growing colonies were picked the following day. In total, 10 colonies were picked.  
After the colonies were picked, they were re-streaked twice on pure sucrose media to further 
refine the selection and to avoid having multiple plasmids in each colony, as observed in the 
second screen. After this a total of 25 colonies were able to grow on sucrose media. 
Plasmids were rescued from the selected colonies and re-transformed into the Sz. pombe 
screening host PY-17. This was done in order to conclude whether one particular plasmid in 
selected TNF-α colony, whose sequence is later deduced, is in fact that which cause a 
selectable phenotype. After the initial growth on glucose media, a liquid invertase assay was 
performed on the re-transformed colonies in order to make a quantitative measurement of 
sucrose hydrolysis (Figure 27). Wt-TNF-α was used as positive control and variant 59 and 60 
as negative control. These negative controls derive from the non-selected randomly picked 
clones from the library. The negative controls do not grow on sucrose plates and importantly 
Glucose 
concentration 
0.01% 0.02% 0.03% Total 
Number of screened 
colonies 
12000 12000 12000 36000 
Positive colonies 
before re-streak 
18 7 
 (1068) 
10 
35 
Positive colonies 
after re-streak 
12 5 8 25 
Positive colonies 
after rescue 
11 5 7 22 
 
Table 2 
The table shows the total number of colonies screened, the number of invertase positive of colonies after the primary selection, 
and number of positive colonies after double re-streaking and plasmid-rescue. The number in the parentheses is the number of 
colonies before replica plating at the glucose concentration 0.03%. 
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do not have a stop codon in the insertion sequence. In other words, these variants are bearing 
insertions at non-permissive sites (for sequence see figure 30). 
Wt-TNF-α displayed activity in the liquid invertase assay, variant 60 did not display any 
activity, and variant 59 displayed a low level. All the selected plasmids were able to 
complement invertase activity in Py-17, except for three (clone 1, 20, and 22). These results 
were complemented by the sucrose growth assay (data not shown). Presumably, this means 
that the three colonies initially isolated, might have contained more than one plasmid after 
screening and re-streaking, and that the plasmid rescued is not the one responsible for the 
invertase positive phenotype.  
From the data it is apparent that the clones exhibit different levels of invertase activity. This 
assay has been reported to be quantitative  (Moreno et al., 1985); however, previous 
experience has proven that the levels vary from experiment to experiment (data not shown), 
and therefore no interpretation is placed on the level of activity. However, the three negatives 
have turned up as negative respectively.  
The reason for the poor reproducibility of the liquid invertase assay is illusive but can be a 
sign that more optimisation is needed to achieve consensus among different analogues 
experiments. Though, it can also represent that differences in plasmid copy-number or growth 
conditions influence the outcome of this assay.  
 
0
0,1
0,2
0,3
0,4
wt #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19 #20 #21 #22 #23 #24 #24 #59 #60
O
D5
40
 Figure 27. Liquid invertase assay on re-transformed colonies.  
The retransformed colonies were grown in Emm-fructose media ON and the normalised to OD600 =1.5. The wt-
TNF-α is included as positive control and two negative controls, which is variants from the randomly picked 
clones before selection (variant 59, and 60).  
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 Analysis of insertion point and sequence of the selected variants 
After having completed the screening, the plasmids from the positive colonies were sequenced 
to identify the insertion point and the sequence of the inserted peptide (Figure 30).  
The linear positioning of the insertion sites 
The distribution of the site of insertion prior to and after selection is examined and several 
differences are apparent (Figure 28). Firstly, the even distribution along the TNF-α sequence 
seen before the selection has shifted to a distribution largely focused in the N-terminal of the 
target protein - especially before the first β-strand, where 10 of the insertion points are 
situated. 14 of the 22 insertions are found between residue 1 and 35. In the middle part of the 
protein between aa 59-119, no insertions are found. In the C-terminal 5 insertion sites are 
found, 2 of which are appended at the C-terminal. 
Secondly, before selection, no discrimination of insertion into secondary structure elements is 
seen. However, the insertion sites after selection are found primarily outside of β-strands, 
with the exception of variant 11 where the insertion is situated in the middle of β-strand 
number 8. Thus, after selection, the insertions are mostly situated in areas of the protein, 
which convincingly can, from a structural point of view, accept insertions. 
And thirdly, before selection a maximum of two insertions was found per site. After selection, 
up to 5 insertions are found, at a single position between proline-13 and valine-14. 
The spatial positioning of the insertion sites 
When looking at the spatial positioning of the insertions (Figure 29), it is apparent that the 
insertion sites fall into three categories; in the receptor-binding domain in the bottom of the 
bell-shape of the trimer, in three up-wards facing loops on the exterior of the lower half of the 
Figure 28. Diagram depicting the distribution of insertion sites prior to and after screening 
The distribution of insertion sites in the amino acid sequence prior and after screening is shown. The barr represent 
an insertion site and the height the number of insertions found. The representation does not discriminate between the 
different reading frame and orientations, so each entry can represent any of the 6 different insertions sequences. 
The colouring of the illustration of the secondary structures below the diagram corresponds to that of figure 12. 
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trimer, and in the interface between the molecules in the trimer (for description of the 
constitution of TNF-α. See introduction page 45).  
The receptor-binding domain comprises the N-terminus and the C-terminus together with the 
loop between β-strands B and C, and the loop between β-sheet F and G (see figure 12). So, the 
insertions at the N-terminal (variant 16, 5, 23, 25, 14, 24, 7, 19, 10, and 21), the loop between 
β-strands B and C (variant 3) and the 2 insertions in the very C-terminal of the molecule 
(variant 13 and 15) are accommodated here. 
The three upward-facing surface orientated loops in which there are found insertions are the 
lower loop between B’ and B (variant 9 and 17), the second lowest loop between A and A’ 
(variant 4, 18, and 12), and the third lowest loop between B’ and B (variant 2 and 6). Notably, 
no insertions were found in the loop between β-sheet E and F, which is the long loop situated 
at the top of the molecule where the insertion of Pharmexa’s current AutoVac candidate 
molecule is found. 
One of the insertions is exceptional (variant 11) in the respect that it is found both in a β-sheet 
and at the interface between the subunits in the trimeric molecule and thereby buried regions 
of TNF-α pointing towards the interfaces of the subunits in the trimer. This is controversial 
when using a rational view on protein folding. 
 
 
 
 
 
 
 
Figure 29 Graphic 3D representation of insertion points in the TNF-α trimer (opposite page).  
  
The image illustrates the insertion points of the peptide insertions after selection. The insertion points in the selected variants are 
indicated as yellow areas and sticks and balls in the accentuate subunit. The number of the variant is indicated by an arrow. If there is 
ore than one insertion at a given point (both identical or in different reading frames), all the variants numbers are indicated in the 
illustration, separated by slashes.   
The images are identical, but rotated in relation to each other. One subunit is displayed in grey with indications of secondary structure 
in colour (red: helixes, green: β-strands), the two other sub-units of the trimer is shown as wire frame or uni-colour ribbons.  
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hTNF 
 MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL  
  
β-strand #  A   A’  B’ B   C   D    E    F  G     H 
 
Possible insertions 
AAAKFVAAWTLKAAA, AAALRVQAATNLAAA, RPLSSLQLGPLRRP, CGRLKGPSCNELSGRT, CGR.VRCSLDP.GGRT, RPP.GSKLQRT.RPH 
 
 
Sequence of Selected clones 
16.MVAAALRVQAATNLAAAMVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL  
 5.MVRAAALRVQAATNLAAAVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
23.MVRSSSRTPSAAALRVQAATNLAAAPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
25.MVRSSSRTPSAAAKFVAAWTLKAAAPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
14.MVRSSSRTPS DKAAALRVQAATNLAAADKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
24.MVRSSSRTPS DKPVAAAKFVAAWTLKAAAPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL  
 7.MVRSSSRTPS DKPVAAAAKFVAAWTLKAAAVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
19.MVRSSSRTPS DKPVCGRLKGPSCNELSGRTVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
10.MVRSSSRTPS DKPVAAAALRVQAATNLAAAVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
21.MVRSSSRTPS DKPALRPLSSLQLGPLRRPQVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL  
 8.MVRSSSRTPS DKPVAHVVACGRLKGPSCNELSGRIAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 4.MVRSSSRTPS DKPVAHVVAAAKFVAAWTLKAAAVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
18.MVRSSSRTPS DKPVAHVVAN PQADAAAKFVAAWTLKAAAAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
12.MVRSSSRTPS DKPVAHVVAN PQAEGAAAKFVAAWTLKAAAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
17.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQCGRLKGPSCNELSGRNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 9.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQCGRLKGPSCNELSGRNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 3.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPLRPLSSLQLGPLRRPQPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
11.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIAAALRVQAATNLAAAPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 2.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRPVRPLSSLQLGPLRRPQP DYLDFAESGQ VYFGIIAL 
 6.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDCGRLKGPSCNELSGRIDFAESGQ VYFGIIAL 
13.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL GAAALRVQAATNLAAAL 
15 MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL CGRLKGPSCNELSGRTL 
 
Sequence of Clones Negative after rescue and retransformation 
1. MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRCGR.VRCSLDP.GGRSRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
22.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KCGRLKGPSCNELSGRT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
20.MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALCGRLKGPSCNELSGRTLLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 
Randomly Picked Library variants 
59 MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY LGAAAKFVAAWTLKAAALGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
60 MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIAAAKFVAAWTLKAAAPIY LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL 
 
Figure 30. The DNA sequence of all the selected variants. The top panel illustrates the secondary structure of TNF-α, where the arrows below show the β-sheets. The colours are identical 
to the ones used in figure 12. The amino acid sequence of the selected variants, the 3 variants failing rescue and 2 non-selected variants, used as negative controls are shown. The 
unselected variants are chosen as they contain PADRE, but fails to induce invertase activity. The underlines amino acids represent β-sheets and the coloured fragment inserts. PADRE 
inserts are green and others are yellow.  
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Reading frame and orientation 
When analysing the insertion sequence frequencies in terms of reading frame and orientation, 
a change in distribution is noted relative to prior selection (Table 3). More sequences are found 
in RF3-r than before selection, whereas the number in RF1-r is reduced. The number of 
selected variants is too small to establish whether this is a significant trend. Logically, 
however, some of the sequences could be more acceptable insertions in the protein than others, 
as they differ in e.g. hydrophobicity/phility, charge, and volume as a consequence of the 
differences in the amino acid composition. Thus, it is not unexpected to observe a change in 
distribution before and after selection. 
Frequency of different 
insert sequences 
Resulting amino acid 
insert sequence  
Frequency prior 
screening 
Frequency after 
screening 
RF1-d (PADRE) AAAKFVAAWTLKAAA  6 (22%) 6 (25%) 
RF1-r AAALRVQAATNLAAA 10 (37%) 7 (29%) 
RF2-d RPLSSLQLGPLRRPQ 4 (14%) 3 (13%) 
RF2-r LRPP*GSKLQRT*RP  - - 
RF3-d CGR*VRCSLDP*GGR  - - 
RF3-r CGRLKGPSCNELSGRT 7 (25%) 8 (33%) 
Total  27 24 
Tabel 3. The frequencies of the different translated insert sequences found in the selected variants.  
The position of the different insertion sequences 
Not only is the position of the insertions interesting, but also the nature of the different 
translated sequences. Firstly, as expected, no stop codons are present after the screen, 
whereas, prior to screening, they constituted approximately 40% of the analysed clones and 
theoretically 33% of un-screened clones. By examining the position of the different insertion 
sequences in the target protein (Figure 31), it becomes apparent that between the amino acids 
proline-13 and valine-14, right before the first β-strand, many different insertion sequences 
can be accommodated without leading to instability of the TNF-α protein. All the 4 possible 
sequences are present here.  
 
Figure 31. Insertions points in the selected variants 
Insertions points are shown as arrows in the primary structure of TNF-α. The 4 different colors represent the 4 
possible amino acid insertion sequences. 
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In contrast, at the position between the amino acids glutamine-47 and leusine-48 (found 
between the β-strand B’ and B) insertions with the sequence resulting from translation of 
RF3-r were found twice. Likewise, at the first 4 amino acid positions at the N-terminus, the 
sequence resulting from translation of RF1-r was found twice, and in the loop between β-
strand 1 and 2 the sequence translating from RF1-d was found twice, indicating that at these 
positions only a particular sequence might be acceptable insertions. 
Variants containing the insertion sequence encoding the PADRE epitope, and, therefore, likely 
vaccine candidates, have been found 6 times at 5 different insertion sites, all situated in the 
N-terminal region of TNF-α.  
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 Recombinant Expression of selected TNF-α variants in 3 systems 
 Recombinant Expression of selected TNF-α variants in Sz. pombe  
The 5 variants containing the PADRE epitope as insert (variant 4, 7 12, 18, and 25) are 
possible AutoVac candidates. They were chosen therefore to verify that the selected proteins 
can fold and be expressed in Sz. pombe, without being fused to the invertase moiety. If the 
variants can be expressed, it will demonstrate that invertase does not drive or influence 
folding. Thus, the cDNA sequence of these TNF-α variants was amplified by PCR and 
reintroduced into the screening vector deleted for the invertase gene. As negative controls, 
variants (59, and 60) were used. These variants do not have the capacity for invertase activity 
as fusion protein, i.e. bearing insertions at non-permissive sites. The wt-TNF-α was included 
as positive control and for investigating the relative expression level between wild type and 
variants.  
Upon expression the TNF-α variants will be secreted into the medium due to the presence of 
the Cpy-signal sequence. Accordingly, the cell culture supernatants were tested using a 
specific TNF-α sandwich ELISA assay for quantification of the protein level of each variants. 
The expression level was normalised relative to the OD600 value of the single cultures at the 
point of harvest (Figure 32).  
The induction time after thiamine repression of the promoter is long, and as the data below 
indicate, longer than the 16 hr described in the literature  (Siam et al., 2004), therefore, the 
expression without thiamine was also tested to see if an increased expression could be 
Figure 32. Expression of wt TNF-α and AutoVac variants in Sz. pombe.  
Two rounds of expression are shown at several time points. A) pre-culture grown in standard EMM-glucose 
medium and B) pre-culture grown in EMM-glucose medium with the addition of 15 ug/ml thiamine. There are 
no data available for variant 25 at 19 hr in un-repressed media 
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obtained by constitutive expression.  
The results show that only wt-TNF-α and variant 25 displayed any protein detectable protein 
levels in the expression medium. wt-TNF-α had a protein level at 5.5 and 10.5 ng/OD600 at its 
highest in unrepressed and thiamine-repressed culture, respectively. The Variant 25 showed a 
comparable expression level at 3 and 6.5 ng/OD600. As seen, the promoter preformed most 
efficiently in the presence of thiamine. 
The lack of detectable protein the other of the selected variants can be due to a lack of folding, 
and hence, expression, but also that the expressed proteins were below the detection level of 
the assay. It is known that Sz. pombe displays large protease activity in the growth media 
(Kumar and Singh, 2004; Tokunaga et al., 1993; Kjaerulff and Jensen, 2005), making the 
proteins liable to degradation, and detection made even more difficult. Therefore, the 
expression was also tested in E. coli and Drosophila cells. 
 Recombinant Expression of selected TNF-α variants in E. coli  
Since not all of the selected variants could be expressed in Sz. pombe, the 5 PADRE variants, 
wt-TNF-α, and the negative controls, variant 59 and 60 were tested for soluble expression in 
E. coli (Figure 33). The proteins were expressed from the pET28 vector in BL21-star cells and 
tested in the ELISA assay. A pET28 vector coding for RANKL is used as control for cross reac-
tivity of E. coli protein in the ELISA. This control displayed no colour reaction in the ELISA. 
The wt-TNF-α showed an expression level at 1000 ng/ml and variant 25 a level at 1500 ng/ml. 
Also, variant 7, 12, and 18 displayed expression levels at 11 ng/ml, 9 ng/ml, and 5 ng/ml, 
respectively. Variant 4 displayed a considerable lower expression level at 0.5 ng/ml. The 
controls displayed no expression. Thus, all of the selected variants showed protein expression. 
However, expression of variant 4 was very low, 2000 times lower than that of wt-TNF-α. Also, 
for the variants 7, 12, and 18 the expression was 100 times lower than that of the wt-TNF-α.  
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Figure 33. Expression of wt TNF-α and 5 AutoVac variants in E. coli Bl21-star.  
The values are displayed on a semi-logarithmic scale due to the large differentces 
between the values 
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 Recombinant Expression of selected TNF-α variants in Drosophila 
The last expression system in which the selected proteins were tested was Drosophila cells. 
This expression system is an important in-house system at Pharmexa, proven very successful 
for expression of human proteins. The variants were expressed transiently in S2 Drosophila 
cells from the p2Zop2F plasmid and secretion was supported by the BiP signal peptide. The 
media were tested with the TNF-α ELISA (Figure 34)  
All selected proteins were tested for detectable levels of protein in the media in ELISA assay. 
The wt-TNF-α showed a protein level at 2.1 ug/ml, and variant 25 an even higher level at 2.4 
ug/ml. The variants 7, and 12, expressed 1.4 ug/ml and the variant 18 1.2 ug/ml. Also, in this 
expression system, variant 4 showed a low, but detectable level of protein at 0.1 ug/ml. None of 
the negative controls showed any TNF-α expression. 
Further, the expression levels of the variants were tested by western blotting. 25ul sample 
was loaded in each lane, which correlates to approximately 50 ng of wt-TNF-α according to the 
ELISA assay. To validate the results from the ELISA, 50 and 100ng wt-TNF-α from a 
standard preparation of protein were also loaded on the gel. As seen, the protein level at wt-
TNF-α and variant 25 corresponds to the expected 50ng, the levels from the variants 12 and 
18 are less than this, and the levels seen for variant 4 are barely detectable. Theses results 
validate the data obtained by ELISA assay. Surprisingly, the protein level of variant 7 is at 
the same level as wt-TNF-α and variant 25, eventhoug the ELISA results indicate a lower 
expression level of this variant. As expected, none of the negative controls displayed any TNF-
α protein.The results from the western blot confirm the protein levels measured by the ELISA 
for all variants, but variant 7. Thus, the ELISA might generally underestimate the protein 
level of variant 7. Furthermore, no degradation of the expressed proteins is detected. 
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Figure 34. Expression of wt TNF-α and the selected AutoVac variants in Drosophila cells. Proteins are 
expressed transiently for 4 days in S2 Drosophila cells. The expression levels are displayed by ELISA and 
westen blot.  
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DISCUSSION 
The need for correctly folded proteins in the AutoVac technology is apparent, as the 
immunological response generated upon vaccination is highly dependent on the recognition of 
spatial B-cell epitopes. However, inserting 15 amino acids of foreign peptide into the target 
protein is a difficult task. Until now the AutoVac proteins have been constructed on the basis 
of predictions from rational design, but a simpler and a less labour-intensive method is of 
obvious value. Furthermore, when using rational design, loops are often the target for 
insertion (Sheridan et al., 2002), but since PADRE is highly susceptible to proteases 
(unpublished data from Pharmexa) a screen might enable identification permissive insertion 
sites within buried regions of the target molecule, resulting in more protease resistant 
AutoVac proteins. In my option, these two approaches can complement each other in the quest 
for the most efficient and stable vaccine molecules. 
Here, I present a complete system for a novel way of generating AutoVac proteins; a folding 
detection assay applied to a random epitope insertion library of TNF-α. 5 different putative 
AutoVac variants of TNF-α were found, 4 of which were expressed at a satisfactory level. The 
system is now ready to generate variants of other targets and/or insertions and to evaluate 
their folding competence. A number of adjustments to the procedure can be made, but a highly 
functional system has been provided. I have focused on the development of the complete 
system, from start to end, in order to prove the functionality, and remove the major obstacles 
of the library and selection system.  
In order to establish this method, I have created a number of novel approaches not previously 
described, including: i) a genetic complementation system for detection of foldable sequences 
in a eukaryotic host, ii) a selection approach to detect the presence of invertase activity using 
a limiting amount of glucose in the selective sucrose media, enabling a selection scheme for 
positive clones.  
 
The epitope insertion library 
Size and randomness of the library 
For generating the library of insertion sequences, a strategy including in vitro transposition 
was used, and this method proved successful. Although the procedure includes several 
reaction steps, it is straightforward and produces a library of good quality. No background of 
wt-TNF-α or transposon hits without insert sequence was found. All the insertions were 
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simple i.e. containing the expected base pairs without any arbitrary insertions or deletions.  
Randomness is another important parameter of the library. On the basis of the results the 
library emerged as random. Only few insertions appeared twice and the insertions were 
evenly distributed in respect to insertion point and direction of the inserted sequence. This 
randomness, combined with the relative size of the library and the size of the TNF-α cDNA 
suggests that the library is exhaustive. This is in agreement with other reports of MuA mini 
transposon integration showing that all phosphodiester bands between the bases in a DNA 
fragment served as targets even though some are hit more frequently than others (Haapa et 
al., 1999). An investigation of the relative frequencies of insertion at the single phosphodiester 
bands could give an estimation of a minimal library size needed and the minimal number of 
variants to screen. Such a randomness analysis could be done by capillary electrophoresis 
using UV or fluorescent detection where the resolution level is at single base pairs. Hereby, 
the relative randomness of different commercially available transposon systems could also be 
evaluated. 
The Insertion sequence 
Insertion libraries made by introducing a DNA fragment of interest into random double-
strand breaks have the inherent feature of translating into 6 different inserts, depending on 
the reading frame and orientation. In the library used in this project, 4 out of the 6 different 
insertion sequences do not contain a stop codon and thus can appear after the screen. 
Consequently, only 5 of the 22 positive clones contained PADRE.  
The insertion points of all the positive variants hold much information as to where in the 
TNF-α molecule there is enough plasticity to accommodate modifications of the protein. 
Furthermore, the fact that there were 4 possible insertion sequences, reveals for each of the 
permissive sites found, whether only one specific sequence is allowed, or if various sequences 
have equal opportunity to be accommodated at this point, and thus stipulate some insertion 
sites are more tolerant than others. 
The insertions translated into other sequences than the PADRE epitope expand information 
attained from the selection procedure. Nevertheless, they are not functional as AutoVac 
molecules. Therefore, generating a library which only translates into TNF-α-PADRE variants 
and introducing stop-codons in the non-PADRE insertions, could be attractive. Making 
different modifications in the insertion sequence could facilitate this. The simplest thing to do 
is to make mutations introducing stop codons in the redundant sequences that are silent in 
the PADRE epitope. This can be done for the sequences of RF2-d and RF3-r (Table 4). This 
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reduces the number of open reading frames to from 4 to 2, one of which codes for the PADRE 
sequence.  
 
 Current insert                        TGCGGCCGCTAAGTTCGTTGCAGCTTGGACCCTTAAGGCGGCCGCA 
 Insert with silent mutations TGCGGCCGCTAAGTTCGTAGCAGCTTGGACCCTAAAGGCGGCCGCA 
 
 Translation of Current insert Translation of insert with 
silent mutations 
RF1-d AAAKFVAAWTLKAAA AAAKFVAAWTLKAAA 
RF1-r AAALRVQAATNLAAA AAALRVQAATNLAAA 
RF2-d RPLSSLQLGPLRRP RPLSS*QLGP*RRP 
RF2-r RPP*GSKLQRT*RP RPPLGSKLLRT*RP 
RF3-d CGR*VRCSLDP*GGR CGR*VRSSLDP*GGR 
RF3-r CGRLKGPSCNELSGR CGRL*GPSCYELSGR 
 
 
Table 4. The consequence of introducing stop codons in RF2-d and RF3-r is shown. The cDNA sequence is 
depicted showing the insert before and after mutation, and the table below illustrates the effect in the 6 different 
translated sequences this change. 
 
Because of the way RF1-r relates to RF1-d (PADRE), the introduction of a stop codon in RF1-r 
will affect the amino acid sequence in RF1-d. Non-silent, but conservative, changes in the 
epitope could be acceptable. Such changes are not likely to influence the outcome of the 
selection and could be changed back afterwards. However, bases which are reverse 
complementary to stop codons in the RF1-r sequence result in histidine, tyrosine, glutamine, 
or aspartic acid residues, or in a stop codon in the PADRE sequence. The introduction of any of 
these residues will lead to non-conservative changes in the PADRE and alter the composition 
of the epitope dramatically; they might obstruct binding capacity to the MHC II molecules or 
the immunogenicity. Therefore, keeping the non-PADRE RF-1r sequence in the library is 
likely giving a much better outcome of the screen.  
The PADRE sequence was identified as a promiscuous and efficient T cell helper epitope based 
on in vitro and in vivo MHC binding tests at Epimmune. Since Epimmune is now a subsidiary 
company of Pharmexa, it may be feasible to evaluate PADRE mutants containing a stop codon 
in their reverse sequence in the MHC binding assays developed at Epimmune to observe 
which amino acid change leading to a stop codon in the reverse sequence is acceptable in 
PADRE; this in respect to immunogenicity or binding capacity to the MHC II molecules. 
Concatenation of the insertion fragments 
A high degree of concatenation of the insertion fragments is seen and is based in the fact that 
the insert DNA was phosphorylated in order to avoid self-ligation of the vector. Another 
approach is to allow discrimination between plasmids containing insert fragment and self-
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ligated plasmids. Destroying the Not1 sites of the variants containing insert fragment, and at 
the same time maintaining the Not1 site, is in the unwanted variants only containing 
transposon derived residues can achieve this. In order to do so, the part of the Not1 
recognition sequences sites present in the insertion fragment is changed, but the sequence of 
the overhang sequence is preserved. Thereby, the capability of annealing to a fragment cut 
with Not1 is maintained, but the recognition site of the restriction enzyme is removed. So, 
after insertion of the fragment and prior to transformation the pool of variants can be 
subjected to Not1 and plasmids without insert being digested. In this way, the insert fragment 
can be made from large un-phosphorylated primers, simplifying the approach for obtaining the 
fragment.  
Including substitutions and deletions in the library 
The Not1 site at the Entranceposon ends results in an extension of the epitope by two 
alanines, and the duplication derived from the transposition includes two extra amino acids in 
the insertion. Reducing the size of the insertions, or making substitutions, may reduce how 
much the insert compromises the stability of the variant protein and can be a means to 
diversify the complexity of the library. This could be accomplished by introducing type 2 
restriction enzymes in the termini of the transposon sequence as previously described for 
other purposes (Jones, 2005). The redundant residues can be removed by including a Mly1 
restriction site flanking one of the terminal Not 1 sites in the transposon. Digesting with Mly1 
and then Not1 after transposition removes the terminal alanines made by the Not1 site and 4 
bases of the 5 bp duplication. Alanine has an interchangeable third codon position; therefore, 
the residual base pair can be integrated in the PADRE sequence. 
Mly1 makes a blunt end cut in the DNA, whereby overhanging bases are only found in one of 
the vector ends and making them incompatible for self-ligation. Therefore, cloning becomes 
easier, and the formation of the concatamers is inhibited. Other type 2 restrictions enzymes 
could make other variations of the mutagenic transposons. E.g. Mme1 removes 20 bp and 
produces a 2 base pair overhang. This end can be filled out by the Klenow fragment or 
alternatively, the insert fragment can contain tails with random overhangs as described by 
Murakami et. al, 2002. The number of bases removed by this procedure can be adjusted by the 
location of the Mme1 restriction sites relative to the Transposon end.  
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The Selection system for foldable protein variants 
The system presented here is carried out on agar solid media in petri dishes, using standard 
laboratory techniques and the availability of an incubator with a shaking device at 30°C as 
sole prerequisite. It is a selection procedure that in contrast to a screen gives the possibility of 
examining a larger number of variants more readily. Furthermore, the selection was shown to 
be highly stringent. The stringency may derive form the use of Sz. pombe which has a highly 
structured and more elaborate secretion system than the one found in S. cerevisiae 
The selection procedure 
The screening procedure consists of three steps: i) selection on sucrose plates with limiting 
glucose, ii) re-streaking of selected clones on sucrose, iii) rescue of the plasmids of the variants 
and re-testing in an invertase assay. 36 colonies were selected on the plates, 25 clones showed 
growth on the sucrose plates, and 22 were positive in the invertase assay.  
For practical reasons, the search for putative AutoVac candidates could progress from the re-
streaking step via yeast colony PCR - where plasmids containing non-PADRE variants can be 
disregarded - directly to testing expression level, and still achieve adequate selection. Only 3 
variants failed the last step of selection i.e. they were not positive in the invertase assay after 
re-streaking - one of which being an obvious false positive after DNA sequencing, as a stop 
codon is present in the sequence. Plasmid rescue and retransformation are important in order 
to deduce the quality of the selection system when it is being developed to know how many 
true positives there are at each step, but this is labour intensive. Therefore, it will be simpler 
to test for expression level and discard the false positives at this step, due to the limited 
number of colonies. This means that the information, as to whether lack of expression is 
caused by a false positive, or by a variant that cannot be expressed, since it is no longer fused 
to the invertase moiety is disregarded.  
The multiple plasmids in the screening host are a drawback of the system and in Sz. pombe no 
low copy plasmids are available, but re-streaking the plasmids twice has largely resolved this 
obstacle. So when using colony PCR to discover the sequence of the variant caution should be 
placed on the possibility of finding more than one plasmid in each Sz. pombe colony.  
Limiting glucose and other parameters for selection 
In this system, the approach using limiting glucose in sucrose media enables a successful 
selection of invertase positive colonies, shown to be not otherwise obtainable. Because the 
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transformed cells can be plated directly on selective media, the necessity of replica plating or 
invertase plate assays is eliminated or reduced thereby reducing workload and occurrence of 
false positives.  
Although secretion of invertase is crucial for growth on sucrose, as little as 0.6% of the wild-
type invertase activity is sufficient to sustain growth on selective medium, and 4.7% results in 
growth rates indistinguishable of that of wild-type cells (Kaiser et al., 1987). Further, as data 
presented here, only 0.1% of glucose in the growth media is sufficient to support growth of 
invertase knockout strains, and these strains are very susceptible for glucose from positive 
neighbour colonies. This is probably the reason that a proportion of the clones 11 out of 36 
picked on the selection plate turned up to be false positives; however, these were easily 
eliminated by the double re-streak procedure on sucrose media. This inconvenience is also 
known from the replica plating procedure (Jacobs et al., 1997), but in this approach false 
positives seem to occur much less frequently than when replica-plating from non-selective 
glucose plates. Altogether, the use of limiting glucose for direct selection of the transformed 
cells is an important improvement of the selection assays using invertase described so far. The 
technique represents, therefore, a new selection assay that could most likely be exploited in 
other systems based on invertase activity as selection marker like the signal sequence trap 
(Jacobs et al., 1997)  
Further experience with the sucrose/glucose concentration ratios in the screen will become 
available as the limiting glucose procedure is used more extensively, e.g. other concentrations 
may be optimal for other targets. Also, the addition of antimycin to the selection plates should 
be tested. This may reduce the number of false positive and/or further enhance the stringency 
of the selection.  
Many proteins fold better at lower temperatures (Baneyx and Mujacic, 2004). In addition, less 
stable proteins not viable at 30°C may be stable at lower temperatures. Therefore, 
temperature could be included as an additional parameter in the selection procedure and/or to 
adjust the sensitivity of the selection.  
The dimension of the screen  
In total, 22 colonies were selected from the 36,000 screened colonies (0.1%). This is equivalent 
to only 2 of the 948 possible variants having folding competence if the screen was exhaustive 
(36000 colonies /948 possible variants ≈ 40 colonies of each variant). The sequences of the 
selected variants show that 20 different insertions were found; therefore, the screen was not 
exhaustive. If the 20 different sequences represented the comprehensive selection of foldable 
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sequences 800 (40 colonies of each variant *20 different variants) colonies could have 
displayed invertase activity among the 36,000 colonies (≈2%).  
The fact that only two of the picked colonies contained the same variant indicates that more 
different sequences are found as folding competent. This could imply that, the true result of 
positive colonies among screened colonies, due to foldable sequences encoded from the 
plasmids, is the 9% of growing colonies seen on the 0.03% glucose plates, before replica 
plating. This taking into account, that 1/3 of the selected clones turned out to be false positives. 
If the number from the 0.03% plates is considered the true number of positives in the library, 
there are approximately 56 folding competent variants in the library (9% of 948 = 85, 1/3 of 85 
= 56). 
However, this screen is not indented as a search for all foldable sequences in the library, but 
simply a proof of concept for the screening procedure. Thus, in order to demonstrate the 
competence of the selection procedure, a limited, and so more manageable, number of colonies 
is picked for analysis. If the screening had been allowed to proceed for more days, more 
positive clones could have been picked. This, in turn, might have resulted in relatively more 
false positives in the different steps of the screen, but also more true positives in total. Some of 
the same variants would probably have been found repetitively, but also new ones.  
The current library has a maximum of only 948 different variants, but the complexity of the 
library can be increased as suggested in paragraph 1.4. Therefore, it is an apparent advantage 
of the invertase-based system that it is a selection procedure in contrast to a screening 
procedure giving the system the dimension to test a large number of colonies. Utilising 
invertase assay may include the qualitative aspect of a screen in the procedure. However, the 
invertase activity, and thus output of the invertase assay, is not only dependent on folding 
competence, but possibly on also folding velocity, as well as, on pre-translational factors 
differing in the variant sequences. Also, the results from the invertase assay are highly 
fluctuant between different rounds of experiments at the present, so some optimisation of 
must be done before full utilisation of this assay. 
Analogous selection and screening systems for foldable sequences 
A comparable protein solubility selection assay has been described in E. coli using the CAT 
resistance gene as selection marker (Maxwell et al., 1999). The selection capacity of this 
system was demonstrated by selecting soluble proteins from a larger pool of insoluble protein 
by mixing the insoluble HIV integrase and a soluble variant in the ratio 10,000:1, and select 
among 400,000 E. coli transformants. After screening 42 colonies grew and out of 18 analysed 
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clones 16 contained the soluble mutant. The selection was prominent, but not absolute and the 
number of non-soluble false positives is comparable to what was found in the invertase 
selection system after re-streaking. Notably, no actual selection was made demonstrating the 
stringency of the system on a complex library. 
Nature has optimised ERAD as detector for folding competence (Ellegaard et al., 2003), and 
therefore, a selection system based on this feature is likely to be highly specific. The 
exploitation of the ERAD systems requires the use of eukaryotic cells with a functional ER 
and Golgi apparatus. Earlier work in S. cerevisiae shows that this feature is in fact functional 
in screens to assess stability of proteins. However, these screens have important drawbacks. 
Firstly, the yeast surface display system (Boder and Wittrup, 2000; Boder and Wittrup, 1997) 
seems specific and finds molecules with the desired qualities. But the system requires both the 
opportunity to perform FACS assay and the availability of highly specific florescent-labelled 
antibodies. Hence, it cannot be carried out by standard laboratory techniques. Secondly, the 
requirement of antibodies makes the system inapt for newly discovered proteins or proteins, 
which beforehand are difficult to express and therefore may have no, or a limited number of, 
available antibodies. Thirdly, if a modification is present in the area for antibody recognition, 
a folded variant will not be detected. The second screen, based on immunodetection of a 
generic tag (Hagihara & Kim, 2002), is applicable to any sequence of interest. Additionally, 
the screen is preformed on colonies growing on solid media in petri dishes. Thereby, the 
method solved the shortcomings of the yeast display system, but the screening procedure is 
not very stringent; many mutations, which passed the genetic screen, did not confer protein 
stability, necessitating additional selection procedures.  
The system presented here improves the possibilities for searching for folding competent 
protein among libraries of variants, compared to other based yeast-systems described in the 
literature. It is stringent, simple, employing common laboratory techniques, relatively labor 
sparing, and can be applied to any targets without prior knowledge or specific detection aids 
for it.  
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Analysis of selected variants  
Permissive insertions must allow energetically favourable and stable protein folding. The 
addition of residues in a protein can be accommodated either by the formation of local 
projections at the exterior of the protein causing small deformations, or by lateral insertion 
induced displacements of the polypeptide toward the protein surface producing loop 
enlargements. If such adjustments in the structure are not possible, the overall structure will 
be distorted. The variants where the insertions are situated in loops protruding at the surface 
of the protein are probably tolerated by extending these loops, whereas the insertions before 
the first and after the last β-strand are probably tolerated by lateral displacement of the 
terminal part of the protein. 
The insertion sites of the selected variants – secondary structure 
After selection 20 different insertions at 16 different insertion sites were found. All, but one of 
the insertions, leave the β-sheets intact. Thus, these insertion points correlate well with the 
secondary structure of the TNF-α molecule. The one insertion site interfering with the 
secondary structure is that of variant 11. This insertion is situated in the middle of a β-strand, 
and thus interferes with the secondary structure. 
The fact that at some positions many different sequences are accommodated demonstrates 
that the selection assay can not only identify permissive sites, but also pinpoint to sites of 
highly plasticity. A site like this could be the obvious target for further construction of 
variants, including substitutions and deletions. 
The insertion sites of the selected variants – tertiary and quaternary structure 
The bulk of insertions is situated at the N-terminal of the TNF-α molecule, which is not 
surprising from the crystallographic data and deletion analysis, revealing that part of the area 
is highly flexible and can be deleted without effect on the structure or biological activity (Jones 
et al., 1989). Moreover, the stabilising properties of lysine-11, around which many of the 
insertions cluster, may help in accommodating the insertions by providing stability to the 
structure in this region, despite the considerable change the insertion of 15 heterologous 
derived amino acids presents to it. 
The N- and C-termini are spatially in proximity, and are part of the receptor-binding domain. 
This domain accommodates 13 of the 22 insertions found, indicating an overall inherent 
flexibility of this region. This agrees with the finding that this receptor-binding domain is very 
diverse among the members of the TNF-α superfamily. This region facilitates contact between 
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ligands and receptors, and it contributes to the specific interaction between the different 
ligand and receptor combinations (Bodmer et al., 2002). Therefore, it is not surprising that 
this domain also has the plasticity to accept insertions.  
The three lower up-wards facing loops on the solvent-accessible surface of the molecule are 
shown to be of a flexible nature (Jones et al., 1989). Also, there are reduced structural 
constraints from the rest of the molecule to extend the loops, relative to loops in buried 
regions. Therefore, it makes good sense that insertions are found here. It is puzzling as to why 
no insertions are found in the two upper loops of the molecule. However, this can be due to the 
fact that the screen was not exhaustive, which may account for the lack of inserts. 
Variant 11 is situated toward the interface of the trimer TNF-α molecule, and is, furthermore, 
situated in a β-strand; this variant is, therefore, somewhat contentious in respect to the 
structural foundation of the molecule. A lateral displacement of β-strand toward the region of 
the N-terminus could be suggested as the means to accommodate this insertion, thereby 
providing space for the insertion. Alternatively, this TNF-α variant may be expressed as a 
monomeric protein, leaving space for the insertion to bulge out in a space otherwise occupied 
by the other subunits in the trimer. Although most TNF-α molecules are found as trimers, 
monomeric TNF-α molecules are to be found in the plasma of humans, mice and rats (Aderka 
et al., 1992; Corti et al., 1992). The oligomerisation state of this variant could be an interesting 
question to address, This can be measured by gel filtration and light scattering after 
expression.  
The ultimate consequences of the insertions on the overall protein structure are simply 
speculative suggestions, inviting to experimental exploration. The exact outcome in the 
protein structure caused by the insertions ultimately must be resolved by protein 
crystallography. Nevertheless, most importantly the selection procedure pinpoints a specific 
region of TNF-α as insertion tolerant.  
TNF-α variants made by rational design compared to selected variants 
It is interesting to compare the insertions sites found by the selection method and the ones 
found by rational design (Figure 35). Variant 4 is found to be foldable both in the screen and 
by rational design. Again the sequence of the two versions is not exactly the same since the 
library-derived insertion sequence has two extra alanines at the end of the insertion. Both the 
library derived and the designed version displayed a very low level of expression. Importantly, 
the fact that this variant is found by both approaches is an indication of the validity of the 
screening approach. 
DISCUSSION 
89 
The most N-terminal insertion site (variant 16) is also found in the rational design, but the 
sequences differ. From the screen only the RF1-r derived sequence (AAALRVQAATNLAAA) was 
found at the most N-terminal part, suggesting that this sequence is most acceptable here. But 
as shown by the designed variant, the PADRE sequence can also be inserted here. 
Two variants with insertions between TNF-α and invertase in the fusion were found after 
screening the library. None of these has the PADRE sequence as insert. A complementary 
variant with PADRE at the C-terminus has been made by rational design, but this variant did 
not show any expression when tested. Although the insertion site is similar, there are several 
dissimilarities between the variants; most notably that the sequences in the insert differ. But 
also, the variants derived from the library are expressed as invertase fusion proteins, and this 
may allow the insertion of a sequence in the C-terminus of the TNF-α protein. 
As seen in figure 35 some regions of the protein can accommodate more than one insertion 
sequence, whereas in others, only the same insert sequence has been found. Although the 
screen is not exhaustive, this gives an indication of the tolerance of insertion of the area, and 
can be utilised if the results from the screen should make the basis for further modifications 
by design. If a variant were to be designed after the results of the screen, it would be obvious 
to choose the N-terminal region, especially the area just before the first β-strand as target for 
insertions. 
The designed variant resulting in the highest expression level is the TNF-α AutoVac molecule 
Figure 35. Insertions points are shown as arrows in the primary structure of TNF-α.  
Top: The insertions found by selection. The 4 different colors represent the 4 possible amino acid insertion sequences. 
AAAKFVAAWTLKAAA (PADRE), AAALRVQAATNLAAA, RPLSSLQLGPLRRPQ, CGRLKGPSCNELSGRT 
Bottom: The insertions predicted by rational design. The insertion sites of PADRE are shown as purple arrows or red 
arrows. Purple arrows indicate an expressible variant, whereas red indicate no expression of the variant. 
 Expression,  No expression 
MVRSSSRTPS DKPVAHVVAN PQAEGQLQWL NRRANALLAN GVELRDNQLV VPSEGLYLIY
SQVLFKGQGC PSTHVLLTHT ISRIAVSYQT KVNLLSAIKS PCQRETPEGA EAKPWYEPIY
LGGVFQLEKG DRLSAEINRP DYLDFAESGQ VYFGIIAL
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with PADRE inserted in the large flexible loop between β-sheet E and F. Here 6 different 
insertions were tried out; of which 3 were expressible (Figure 36). One of these is a simple 
insertion into the flexible loop (TNF4). Although it could be anticipated that a variant 
corresponding to TNF4 should have appeared after selection from the library presented here, 
such a variant was not found. This could simply be because the screen was not exhaustive, 
and screening a larger number of clones would have revealed this variant. Another reason 
may be that the variant from the library corresponding to TNF4 does not have folding 
competence. Variants generated in the library have at least 2 additional residues on each side 
of the inserted peptide, compared to variants based on rational design (see Figure 36). As 
seen, even small differences in the insertion may be sufficient to compromise folding and cause 
the cessation of expression; this may explain that the selection did not result in a TNF4-like 
variant.  
   103   112 expr. 
TNFα RETPEG-----------------AEAK  + 
TNF4  RETPEG--AKFVAAWTLKAAA--AEAK  + 
TNF5  RETP----AKFVAAWTLKAAAEGAEAK  - 
TNF6  RETPE---AKFVAAWTLKAAA-GAEAK  - 
TNF7  RETPEG--AKFVAAWTLKAAA---EAK  + 
TNF8  RETPEG--AKFVAAWTLKAAA-----K  + 
TNF9  RETP----AKFVAAWTLKAAA-----K  - 
 
TNFlib RETPEGAAAKFVAAWTLKAAAEGAEAK  ? 
 
Figure 36. The TNF-α AutoVac made by rational design  
The figure depicts the TNF-α variants in the flexible loop 3 (arginine-103 to lysine-112) made from suggestions 
based on rational design. The latter variant depicts how the corresponding library variant looks. The figure is 
modified from Nielsen et al. 
Expression of variants in different expression systems  
In order to verify that invertase does not drive or affect folding and the variants could thus be 
expressed after removal of the invertase moiety, the 5 selected variants holding the PADRE 
insertion were tested for expression in Sz. pombe, E. coli and Drosophila, as these are 
potential AutoVac protein candidates. All five variants were expressed as soluble proteins in 
E. coli and were secreted in Drosophila. It proved difficult to express the TNF-α protein in the 
Sz. pombe system and in the variants even more so. Other reports of Sz. pombe expression 
have shown this to be a common phenomenon, due to extended protease activity in the growth 
media (Kumar and Singh, 2004; Tokunaga et al., 1993; Kjaerulff and Jensen, 2005).  
All tested proteins could be expressed after removal of the invertase moiety, indicating that 
not only the tested, but in fact all the selected proteins have folding and expression 
competence without the invertase moiety. Hence, the selection procedure appears to be very 
stringent. Furthermore, even if Sz. pombe will not be used as expression host due to the low 
expression level and protease secretion, the system is able to detect proteins with folding 
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competence that exceeds the host system, making apparent its value as a screening host. The 
low expression level of the Sz. pombe in fact may be an advantage to the screen, as it might be 
a crucial factor of the high stringency of the system. 
Differences expression level between the selected variants 
Variant 4 only showed a detectable level of protein in the Drosophila and E. coli expression 
systems, but in both, it was the variant with the lowest yield. A variant similar to that of 
variant 4 had been made by rational design, and also this designed variant did show 
expression in E. coli. However, both the selected and the designed variant displayed very low 
yields of soluble protein. Variant 4 is the sole of the tested variants where the insertion 
violates a β-strand. This β-strand disturbance could lead to instability of the protein structure; 
it may be at the rim of mis-folding, and therefore giving the poor expression. 
The variant with expression in all systems and the highest expression level both in Sz. pombe 
and E. coli is variant 25. The level even exceeds that of the wt-TNF-α. Since the stability and 
secretions levels of proteins have been reported to correlate (Kowalski et al., 1998), the high 
expression level of this variant may indicate a protein stability comparable to the wt-TNF-α 
protein. Further, since the low levels of detectable protein in Sz. pombe are generally owing to 
protease activity in the expression media, this system gives an indication of the variants 
resistance to proteases and following the quality of the tightness of globular protein structure, 
as protruding peptide segments are more prone to be substrate for proteases. Therefore, the 
viability of the variants in this environment can indicate the degree interruption of the 
insertion on the protein structure. Variant 25 is the only protein variant detectable in Sz. 
pombe, and this point towards a very stable protein structure in which the disturbance of the 
insert in the TNF-α structure is negligible. The fact that the expression level of variant 25 in 
E. coli is comparable to that of wt-TNF-α would in principle make it a candidate to move 
further on in the process of vaccine development, which comprises large-scale fermentation, 
protein purification, and immunological testing. In particular, it would be highly interesting to 
analyse the protein chemical and immunological properties of these new TNF-α variants, 
including structural comparison with wt-TNF-α, stability and immunogenicity. Structural 
comparison could be done e.g. by CD-spectroscopy and light scattering. Stability could be 
investigated by in thermal denaturation studies using CD-spectroscopy and/or differential 
calorimetry. Immunogenicity studies could comprise vaccination of mice and characterisation 
of the resulting antisera as to TNF-α antibody titer, and ability to cross-react with and 
neutralise wt-TNF-α. Ultimately, the new TNF-α variants should be evaluated in a relevant 
disease model such as rheumatoid arthritis murine models for therapeutic effect. 
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In conclusion, the screening approach is able to useful in order to find foldable protein capable 
of being expressed in a soluble form. There was found one AutoVac candidate that could be 
moved on as an E. coli expression project. In Drosophila 4, out of the 5 variants showed an 
expression level beyond 1:g/ml, which is the level considered satisfactory for AutoVac 
candidates in a Drosophila expression project at Pharmexa. This means that the task set out 
for my PhD project has been fulfilled. 
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Other applications of the library-selection system 
The expression of heterologous proteins is a general requirement in many areas of protein 
science and molecular biology, as well as in biotechnology. A solubility assay can be useful 
when improving protein functions or solubility by optimising the primary sequence using 
single amino acid substitutions (Petrounia and Arnold, 2000; Jones, 2005). Furthermore, more 
extreme changes, as by the AutoVac technology, calls for the use of a strategy for selection of 
soluble proteins. 
Application: Protein dissection  
The vaccine targets, to which the AutoVac technology can be applied, may be large multi 
domain proteins. In general, large proteins are often difficult to express recombinant and often 
result in heterogeneous products. For such proteins, it will be advantageous only to use a 
smaller part of the protein in a vaccine. This part with an epitope insertion will be sufficient to 
induce an immune response. The described system would be very applicable for identifying 
small domains in a larger protein having the potential to achieve a foldable structure. The 
transposons can generate both N-, and C-terminal mutants at random, and this, combined 
with the selection system identification of properly folded truncation mutants, is possible. 
This system could also be used outside Pharmexa for identification of important regions of 
protein structure and function in general  (Stemmer, 1994). Moreover, structural genomics are 
often limited by the ability to produce or acquire soluble protein variants for crystallography 
and high solubility strongly correlates with success in structural studies. The need for a mean 
to obtain soluble proteins is enhanced after the sequencing project for several organisms has 
been completed. It may not be possible to produce proteins their full length e.g. due to 
membrane spanning domains, and the method described here could provide a tool for 
definition of properly structured domains of proteins of interest. 
Application: Multi component proteins 
Similarly, the transposon system can also facilitate the generation of a library of stable hybrid 
molecules (Naumann et al., 2002). Using transposition, two proteins can be linked together via 
transposon insertion in the N-terminus of one protein of interest and C-terminally of another. 
The two proteins are assembled using the restriction sites from the transposons. In the 
context of AutoVac the epitope could be situated between the protein moieties. Alternatively, a 
variant containing an epitope could be found prior to protein fusion. The selection procedure 
can now be applied to find hybrid variants that are both in-frame with each other and 
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foldable. The described system could also be of value for other applications, e.g. making multi-
component enzymes  (Wells et al., 1985). 
 
Conclusion 
I have developed a general method to find expressible vaccine proteins which contain a foreign 
Th-cell epitope. With this project I have provided a means to generate an exhaustive insertion 
library with precise epitope insertions, and a stringent eukaryotic selection system for folding 
competent proteins, and thus a valuable tool in the generation of AutoVac candidates for 
Pharmexa. This method can advantageously complement the “trial and error” and rational 
design approaches used so far; it enables the generation of a larger panel of identified 
candidates, it potentially provides more candidates for immunological evaluation, and it 
reduces current bottlenecks in the research phase. 
During the course of this work 4 novel putative TNF-α vaccine candidates were found. These 
candidates revealed interesting epitope insertion sites, not earlier investigated in Pharmexa’s 
TNF-α vaccine development program. These novel TNF-α AutoVac variants represent 
therefore promising candidates to move further in the process of vaccine development via 
large scale fermentation, protein purification and immunological testing. 
Conclusively, based on the presented results, I would strongly advocate for Pharmexa to 
implement this method in the future quest for AutoVac candidates. 
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MATERIALS & METHODS 
Cloning procedures 
Standard cloning procedures were carried out according to Samsbrook and Russell, 2001. All restriction 
enzymes were pursed from New England Biolab and all primers from DNA technology. PCR reactions 
were preformed using Expand PCR system (Roche) according to manufactures instructions. The E. coli 
strain DH10b (Invitrogen) is used for cloning purposes, and grown in liquid or agar solid LB-media 
(Invitrogen) containing 50 µg/ml Carbencillin (Sigma). Vectors and inserts were ligated together using 
T4 ligase. All plasmids are sequenced in a region covering modifications to check the fidelity of the 
constructs, using the BigDye kit (Applied Biosystem) and run at the ABI PRISM 310 Sequence analyser 
(Applied Biosystem). 
 
Library plasmid 
Insertion mutagenesis by transposon was carried out in a modified pUC19 vector. The pUC19 plasmid 
(Invitrogen) was linearised by the restriction enzymes Nde1 and Hind III. The wt-TNF-α gene was 
amplified using PCR and the primers 5’GCACCATATGCCATGGTGCGCTCAAGCTCGCGCACGCC 
GA3’ and 5’TTACGCCAAGCTTGAGCTCCCAATGCGATAATGCCGAAGTAGACC3’. The resulting DNA 
fragment is cut by the restriction endonucleases Nde1 and Hind III.  
 
PADRE-pVax 
The pVAX plasmid (Invitrogen) was lineased by restriction with Not1. The insert was made by 
annealing the two primers 5’GCGGCCGCTAAGTTCGTTGCAGCTTGGACCCTTAAGGCGG3’ and 
5’CCGCCTTAA GGGTCCAAGCTGCAACGAACTTAGCGGCCGC3’. (The PADRE –pVAX plasmid was 
made by Sven Muller) 
 
Transposition 
The MuA transposon reaction kit was acquired from Finnzymes and carried according directions. The 
transposon was removed by the restriction enzyme Not 1 succeeded by CIP dephosphorylation. The 
transposon was interchanged with insert fragment from plasmid PADRE-pVAX also cut with Not1.  
 
Sz. pombe Screening host, Screening Plasmid, and transformation  
The Sz. pombe invertase knockout strain was generated from Eg660 ∆inv1::ura4+ obtained from O. 
Nielsen (University of Copenhagen), using a one-step gene replacement technique described by 
Rothstein, 1983. The primers used for amplification of the invertase gene and flanking sequences were 
5’ATCTAGACAAAATACATCTTATGTATTGAACATTAG3’ and 5’AGAATTCGCAAATGCCACTAGCTAA 
AATATATTTC3’. Correct integration was confirmed by PCR. 
The invertase gene was cloned from the Eg660 strain using the primers 5’ACCATGGCTCCCCGTCACT 
TATATGTAA3’ and 5’AGCGGCCGCTTAGCAATTCCAGATAGTCTTTAATG’3 was introduced in the 
pREB3X1 vector by the restriction enzymes Nco1 and Not1. A Not1 and Sac1 restriction site was 
destroyed by restriction of the relevant enzyme, end-filling by T4 ligase and re-ligation. A Sac1 
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restriction site and a stop codon was introduced in frame between the Cpy-signal sequence and the Inv 
gene by the primers 5’TATCCATGGCATGAGCTCCCCGTCACTTATATGTAAAACG’3 and 5’CAGTGG 
TATACGCAATAGCCTG’3. The fragment and vector were digested with the restriction enzymes Nco1 
and BspEI. The library of variants was transferred from the pUC19 -based plasmid to the screening 
plasmid using the restriction enzymes Nco1 and Sac1. (The screening vector and host was made by 
Søren Kjærulff) 
 
Sz. pombe transformation 
Sz. pombe transformations were performed using a PEG [poly (ethylene glycol)]/lithium acetate 
procedure  (Moreno et al., 1991). The expected transformation frequency is 104 to 106 per ug of DNA. 
This can, however, vary significanltly. This may by a concequence of the exact growth status of the cells 
at harvest time. Grow 150 ml culture in EMM medium at 30°C to a density of 1 - 2 x107 cells/ml. 
Harvest the cells at 3000 rpm for 5 min at room temperature. Wash cells in 40 ml of H2O and spin them 
down as before. Resuspend the cells at 1 x 109 cells / ml in 0.1 M lithium acetate (adjusted to pH 4.9 
with acetic acid) and dispense 100 µl aliquots into Eppendorf tubes. Incubate at 30°C for 60 - 120 min. 
Cells will sediment at this stage. Add 1 µg of plasmid DNA in 15 µl TE (pH 7.5)/H20 to each tube and 
mix by gentle vortexing, completely resuspending cells sedimented during the incubation. Do not allow 
the tubes to cool down at this stage. Add 290 µl of 50 % (w/v) PEG 4000 prewarmed at 30°C. Mix by 
gentle vortexing and incubate at 30°C for 60 min. Heat shock at 43°C for 15 min. Cool the tubes to room 
temperature for 10 min. Centrifuge at 2000 rpm for 2 min in an Eppendorf centrifuge. Carefully remove 
the supernatant by aspiration. Resuspend the cells in 1 ml of 1/2 X YEA by pipetting up and down with 
a P1000. Transfer the suspension to a 50 ml flask and dilute with 9 ml of 1/2 YEA Incubate with 
shaking at 30°C for 60 min or longer. Cells are washed twice in Emm-sucrose media before plating on 
selection plates with freshly made ultra pure sucrose (filter-sterilised). 
 
Edinburgh minimal medium (EMM) 
EMM with the different carbon sources were prepared as described  (Moreno et al., 1991). The medium 
contains Potassium phthalate (3 g/L), Na2SO4 (0.04 g/L), ZnSO4 (0.4 mg/L), Na2HPO4 (2.2 g/L), 
Pantothenic acid (1 mg/L), FeCl2 (0.2 mg/L), NH4Cl (5 g/L), Nicotinic acid (10 mg/L), Molybdic acid (40 
µg/L), Myo-inositol (10 mg/L), Potassium Iodide (0.1 mg/L), MgCl2 (1.05 g/L), Biotin (1 mg/L), CuSO4 
(40 µg/L), CaCl2 (14.7 mg/L), Boric acid (0.5 mg/L), Citric acid (1 mg/L), KCl (1 g/L), MnSO4 (0.4 mg/L). 
  
Plasmid Rescue 
The plasmid rescue were made by harvesting 5 ml of Sz. pombe culture OD600=1. The cells are harves-
ted and washed once in 5 ml milliQ H2O. 500µl extraction buffer (100mM Tris (pH 7.6), 10 mM EDTA, 
1% SDS, 0.2 M NaCl) and glass beads until 2 mm below the liquid surface was added. 500 ul Phenol/ 
Chloroform/isoamylalcohol (25:24:1) is added and the sample is submitted to 15 sec of shaking in the 
Fast-Prep. The Phenol phase is removed after centrifugation for 5 min at 20000 rpm. One more phenol 
extraction is done and the DNA is extracted by making EtOH precipitation twice. The plasmid DNA is 
now ready for transformation into E. coli. The plasmid yield is not low, so highly competent cells must 
be used. 
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Yeast Colony PCR 
Due to an extended DNase activity in the cells, a successful colony PCR is highly dependent of the time 
passing between cell lysis and the onset of the PCR reaction. Hence, the PCR mix are prepared prior to 
cell lysis and kept on ice. The cell lysis is achieved by harvesting cells from 1 ml Sz. pombe culture of in 
exponential growth, adding 500 ml of extraction buffer (100mM Tris (pH 7.6), 10 mM EDTA, 1% SDS, 
0.2 M NaCl) and 250 ml glass beads. The mixture is submitted to 15 sec in the Fastprep and cell debris 
is spun down for 1 min at 13000 rpm. 1 ul of the supernatant are transferred to the PCR reaction and 
standard PCR (prepared according to manufactures instructions) are preformed. 
 
Invertase overlay solution: 
50ml (10 plates), 30 ml H2O, 2.15 g Sucrose, (Ultrapure invitrogen), 5.0 ml 1.0M Sodium acetate buffer 
(pH5.5), 1.0 ml 20mM N-ethylamide (NEM) , 0,5 mg Horseradish peroxidase (HRP), 100 ul Glucose 
oxidase (1000 u/ml) , 30 mg Dianisidine, 10 ml Agar solutin 3% in H2O (50°C).  (Darsow et al., 2000) 
 
Liquid Invertase assay:  
Grow Cell culture ~ 5x 106 cells/ml, Normalize the different cell cultures to the same OD600, Spin 1000 
µl culture, Resuspend cells in 1 ml media, wash in 1 ml Media, Resuspend cells in 1 ml media. 
10 µl cell culture+ 80 µl Media + 10 µl Sodium acetate buffer, 1.0 M (pH 4.9) (made from 17,5 M acetic 
acid pH adjusted with 6M NaOH). Add 25 µl Sucrose 30%, incubate 30 min at 30°C. Add 19,5 µl 0,2M 
K2HPO4 (pH 10.0) incubate 3 min at 100°C. The change to a basic pH takes the enzyme out of its active 
range and also renders the enzyme more sensitive to heat treatment. Spin down. Transfer supernatant 
to cuvettes. Add 1 ml invertase assay solution (39 ml K2HPO4 Buffer 0.1 M pH 7.0, 200 µl N-ethylamide 
(NEM), 20 mM, 100 µl Horseradish peroxidase (HRP), ML/ml, 80 µl Glucose oxidase, 1000 units/ml, 600 
µl Dianisidine 10 mg/ml. Stocks of NEM, HRP, and dianisine can be made in advance and stored at 4°C. 
Dianisdine should be stored in a light-proof bottle). Incubate 30 min at 30°C. Add 1 ml of 6 N HCl. 
Measure OD540 (Darsow et al., 2000). 
 
Sz. pombe plasmid and recombinant expression 
Plasmids of the variants Sz. pombe plasmids containing Wt and variant protein were made by PCR 
amplification of the insert cDNA from the screening vector by the primers 5’CGTTTTACATATAA 
GTGACGGGGAGCTCAGAGGGC3’ and 5’CCGGGTCATCATTACTATTACTAACGAGCT3’, and cut with 
the restriction enzymes Nco1 and Sac1. The pET28 vector was linearised with the restriction enzymes 
Nco1 and Sac1, and insert and vector ligated together.  
A single Sz. pombe colony was grown ON in a 3 ml pre-culture Emm-glucose media containing 2% 
Broad bean peptone and 15 uM thiamine or no thiamine. Expression was commenced at OD600 =0.2 
inoculated from the ON cultures. The expression media was 10 ml EMM-glucose media containing 5% 
Broad bean peptone (Fluka) and CS-LEU amino acid supplement (Q-BIO gene). Media and cells were 
separated by centrifugation at 3000 rpm for 5 min at room temperature. Media supernatants were 
tested in the TNF-α ELISA. 
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E. coli expression plasmids and recombinant expression  
5’CGTTTTACATATAAGTGACGGGGAGCTCAGAGGGC3’ and 5’CCGGGTCATCATTACTATTACTAAC 
GAGCT3’ and cut with the restriction enzymes Nco1 and HindIII. The pET28 vector was linearised 
with the restriction enzymes Nco1 and HindIII, and insert and vector ligated together. 
Bl21-star cells transformed with the relevant plasmids and grown in a 5 ml ON culture. Cells were 
inoculated to an OD600 = 0.04 in 50 ml LB media with 60 ug/ml Kanamycin in shake flasks at 37°C. At 
OD600 = 0.7 IPTG was added to a concentration of 1 mM to initiate expression. After 5 hr of expression 1 
ml cells were harvested and 1 ml sonication buffer were added ( 20mM Bis-Tris pH 6.0,40 mM NaCl, 10 
mM EDTA) together with Complete protease inhibitor, according to manufactures instructions. Cells 
were sonicated on ice 4 times 15 sec at 11 Amp, with 20 sec interruption between. Cells were 
centrifuged at 20000 rpm in 4°C for 20 minutes and supernatants were tested in the TNF-α ELISA. 
 
Drosophila plasmid and recombinant expression 
The TNF-α and variants cDNA were amplified from the screening vector by the primers 5’TCAGCTG 
AATTCCCGATCTCAATATGAAGTTATGCATATTACTGGCCGTCGTGGCCTTTGTTGGCCTCTCGCTG
GATGGTCAGATCATCTTCTCGAACCCCG3’ and 5’CGGTCTAGAGGATCCATCACTATTAGAGGGCAA 
TGATCCCAAAGTAGACCTGCCC3’ and introduced into p2Zop2F vector linearised with the restriction 
enzymes HindIII and BamHI.  
Drosophila S2 cells (ATCC CRL-1963) were used as expression host. Plasmid transfection was done 
using the Saint-18 transfection reagent (Cytotech). 3 ug of DNA is mixed with 300ul serum and 
antibiotic free media. 25 ul of Saint 18 transfection agent is mixed with 300 ul serum and antibiotic free 
media the two solutions are mixed and incubated at room temp 10-15 min. Media is remove from cells 
grown to a density of 106 cells/ml, and they are rinsed with 5 ml serum-free media. 2.5 ml serum free 
media is mixed with transfection solution and added to the cells, and they are incubated for 18 hrs at 
37°C. Hereafter, the media is replaced with 4 ml Excell-420 media (JRH Biosciences) with 10% FBS in 
25 cm2 T-flasks at 37°C and grown for 4 days. Media and cells were separated by centrifugation at 3000 
rpm for 5 min at room temperature. Media supernatants were tested in the TNF-α ELISA and in 
western blot. 
 
ELISA quantification of protein 
To 96 well Maxisorp micro titter plates were added 100 ul coat antibody Z0109 (Dako), diluted 1:1000 in 
coating buffer (3.18 g/l Na2CO3, 5.85 g/l NaHCO3, pH 9.0); 150 ul blocking buffer (1 % PBS in 10mM 
phosphate/150 mM NaCl buffer, pH 7.2); 100 ul Capture antibody mAB210 (R&D Biosystems) diluted 
1:1000 in Dilution buffer ( 0.05% Tween 20 (Sigma), and 1 % PBS (Sigma) in 10mM phosphate/150 mM 
NaCl buffer, pH 7.2) ; 100 ul Detection antibody BAF210 (R&D Biosystems) diluted 1:500 in Dilution 
buffer; 100 ul Streptavidine-HRP RPN1231V (Amersham) in Dilution buffer; 100 ul of OPD (Sigma) 10 
mg in 25 ml colour buffer (7.3 g/l Citric acid*H2O,11.86 g/l Na2HPO4*H2O) with 10 ul H2O2 (Riedel-
deHaën). Between each step the plates were washed 3 times with wash buffer (10 ml/l TritonX100, 29.3 
g/l NaCl, 0.2 g/l KCl, 0.2 g/l KH2PO4, 1.15 g/l NaHPO4*2H2O, pH 7.2). The colour reaction was stopped 
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adding 100ul of 1M H2SO4 and the plates were read at 490/630 nm.  
 
Western blot 
25ul of sample were loaded on NuPAGE 4-12% SDS gels (Invitrogen) together with 50ng or 100ng of E. 
coli derived standard wt-TNF made at Pharmexa. Samples run and blotted according to manufacturers 
instructions. Antibody dilution, blocking, and wash was preformed in ECL buffer (250mM Tris, 750 mM 
NaCl, 25mM EDTA, 0,5% NP-40, pH7.4) The blot was blocked for 2 hr and then incubated with primary 
antibody (polyclonal anti-TNF-α, generated in-house at Pharmexa) diluted 1:1000 for 1 hr, and 
secondary antibody goat-anti-rabbit (DAKO p448) diluted 1:2000 for 1 hr. Between each step the blot 
was washed for 3 x 20 min in ECL buffer. 
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